

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07F 9/6561, A61K 31/675, C07H 19/16, A61K 31/70	A1	(11) International Publication Number: WO 96/33200 (43) International Publication Date: 24 October 1996 (24.10.96)
(21) International Application Number: PCT/CZ96/00011 (22) International Filing Date: 19 April 1996 (19.04.96) (30) Priority Data: 08/426,372 21 April 1995 (21.04.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/426,372 (CIP) Filed on 21 April 1995 (21.04.95) (71) Applicants (for all designated States except US): ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY [CZ/CZ]; Flemingovo nám. 2, 166 10 Praha 6 (CZ). REGA STICHTING, V.Z.W. [BE/BE]; Minderbroedersstraat 10, B-3000 Leuven (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): HOLÝ, Antonín [CZ/CZ]; Trebešovská 1699, 193 00 Horní Počernice (CZ). DE CLERCQ, Erik, Desire, Alice [BE/BE]; Parklaan 9, B-3360 Lovenjoel (BE).		(74) Agent: GABRIELOVÁ, Marta; Inventia, s.r.o., Třída Politických vězňů 7, 111 73 Praha 1 (CZ). (31) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NOVEL COMPOUNDS AND METHODS FOR THERAPY (57) Abstract Novel PMP, PME and HPMP and related compounds containing N ⁶ and/or 2-substituted 2,6-diaminopurine, 2-aminopurine and adenine bases are provided. These compounds are useful in a variety of utilities, including as intermediates in the preparation of flame retardants, diagnostic reagents and therapeutics, including antivirals. Of particular note are compounds, particularly the (S) enantiomers otherwise not known to possess anti-DNA viral activity that become potent inhibitors of DNA viruses particularly upon substitution of the N ⁶ site, thereby providing a novel, unexpected and surprising use for such compounds. N ⁶ substituted compounds herein also have been shown to suppress immunostimulation.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

NOVEL COMPOUNDS AND METHODS FOR THERAPY

10

This application relates to nucleotide analogues and to their use in suitable utilities, especially diagnostic and therapeutic methods. It also relates to the use of such nucleotide analogues as haptenic labels.

Nucleotide analogues containing phosphonate groups are disclosed for
15 example in U.S. Patents 4,659,825, 4,808,716, 4,724,233, 5,142,051, 5,302,585, 5,208,221, 5,352,786, 5,356,886, in EP publication numbers 269,947, 481,214, 630,381, 369,409, 454,427, 618,214 and 398,231 and in WO 95/07920 and WO 94/03467. The teachings of these patents include compounds in which a phosphonate group is linked to a defined purine base, generally at the 9-
20 position of the base, by a 2-(methoxy)propyl group, a 2-(methoxy)ethyl group, a 2-methoxy-3-hydroxypropyl group, or a 2-methoxy-3-fluoropropyl group, known respectively as PMP, PME, HPMP and FPMP compounds. The purine bases may include the aza and deaza analogues thereof. Typical purine bases are adenine, 2,6-diaminopurine and guanine.

25 U.S. Patent 5,142,051 discloses an (RS) HPMP compound in which the purine base is N⁶-dimethyladenin-9-yl.

EP 454,427 includes disclosure in which the purine bases of FPMP compounds are substituted by substituted amino (alkylamino disclosed).

30 EP 468,119 describes certain methoxyphosphonate antiviral agents in which a purine heterocyclic base is substituted at the 6 position with "NHR" and at the 2 position with H or NH₂, but R is undefined.

EP 481,214 discloses certain methoxyphosphonate antiviral compounds as antiviral agents for RNA or DNA viruses where the purine base is independently substituted at its 2 or 6 position with NHR⁵ or N(R⁵)₂, wherein
35 R⁵ is C1-C20 alkyl, aryl or aryl-alkyl which may be substituted or unsubstituted by substituents independently selected from the group consisting of hydroxy, oxygen, nitrogen or halogen.

WO 94/03467 discloses PMP compounds for use in treating retroviruses in which the heterocyclic base is a purine or its analogues in which the 2



and/or 6 and/or 8 position is substituted by, among other things, alkylamino, aralkylamino, dialkylamino, heteroalkylamino, alkyloxyamino or heterocyclic amino, wherein alkyl is straight or branched chain saturated hydrocarbyl group containing C₁-C₆, such as methyl, ethyl, 2-propyl, n-pentyl or neopentyl;
5 alkyloxy is O-alkyl; aralkyl or heteroaralkyl is -R-Ar where -R- is the alkylene counterpart of alkyl (-R) and Ar is a substituted (with hydroxyl, halo, amino, sulfonyl, carbonyl or C₁-C₃ alkyl substituted with hydroxyl, halo, amino, sulfonyl, or carbonyl) or an unsubstituted aromatic group having 6-10C and optionally a heteroatom selected from oxygen or nitrogen, e.g., phenyl,
10 naphthyl, quinolyl or benzyl; aralkylamino and heteroaralkylamino are defined as groups of the formula -N(Z)₂ wherein Z is independently H or -R-Ar (but at least 1 Z is -R-Ar); heterocyclic amino is a saturated or unsaturated heterocyclic ring containing at least 1 N atom (ordinarily 1) and optionally in addition at least 1 other heteroatom (examples being pyrrolidine, morpholine
15 or piperidine). WO 94/03467 discloses that cyclic structures contain from 3 to 6 ring atoms and are monocyclic, and in some embodiments the substituents of purine 6-amino groups are taken together with purine N¹ to form an N-heterocycle fused to the purinyl moiety, as in N¹-N⁶-ethenoadenine.

WO 94/03467 discloses a number of specific N⁶-substituted(R)-PMPDAP
20 compounds, including 9-(R)-(2-phosphonomethoxypropyl)-2-amino-6-cyclohexylaminopurine and 9-(R)-(2-phosphonomethoxypropyl)-2-amino-6-cyclopropylaminopurine.

WO 95/07920 discloses various antiviral methoxyphosphonate compounds having protected heterocyclic bases in which amino groups are
25 mono substituted with C₁-C₂₀ alkyl, wherein alkyl includes straight chain, branched or cyclic residues, including methyl, ethyl, propyl, cyclopropyl, isopropyl, n-, sec-, iso-, and tert-butyl, cyclobutyl and "cyclic N-, S- or O-heterocarbonyl" (such as piperidinyl or morpholino).

EP 434,450 discloses certain non-phosphonyl nucleoside analogues
30 containing 2,6-diaminopurine wherein the 6 position of the 2,6-diaminopurinyl base is substituted with cyclopropylamino or N-cyclopropyl-N-methylamino. EP 421,819 discloses a similar nucleoside analogue in which the substitution is cyclopropylmethylamino. Daluge et al. (34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Oct. 4-7, 1994)
35 discloses carbovir derivatives in which the 6 position of the purine is substituted with cyclopropylamino, N-cyclopropyl-N-methylamino or N-aziridinyl.

Cihlar et al., "Antimicrobial Agents and Chemotherapy" 39(1):117-124 (1995) disclose N⁶-aminohexyl-PMEDAP.

Holy et al., "ACS Symp. Ser." 401:57-71 (1989) and Holy, "Kem. Ind." 38(10):457-462 (1989) describe the antiviral activity of certain N⁶-substituted nucleotide analogues.

It is an object of this invention to provide antiviral compounds having an improved selectivity index, i.e., that are less toxic yet more efficacious than nucleotide analogues known heretofore.

It is an object to prepare compounds that are suitable as haptenic labels for oligonucleotide probes and polypeptides.


It is an additional object to provide compounds useful in the preparation of fire retardant resins.

It is a further object to obtain nucleotide analogues that are useful as anti-infective agents.

It is another object of this invention to provide compounds useful in the treatment of DNA viruses.

Summary of the Invention

The objects of this invention are accomplished by a method comprising treating a subject infected or at risk of infection by a DNA virus with a therapeutically acceptable dose of a compound having structure (1)



wherein

Y independently is OH, -OR³, -OCH(R¹⁶)OC(O)R³, a monophosphate, a diphosphate, an amino acid amidate, a polypeptide amidate, -NHR³, or -N(R³);

R³ independently is unsubstituted alkyl, aryl, alkenyl, alkynyl, alkaryl, alkynylaryl or alkenylaryl; R³ substituted by C₁-C₆ alkoxy, C₁-C₆ carboxylalkylester, halo, carboxy, hydroxyl, cyano, nitro, N-morpholino, or amino; and/or R³ wherein -CH₂- has been substituted by NH, S, or O;

R^{2'} and R² independently are halo, NH₂, X or H, but at least one R² is X;

R¹ is CH₃, C≡CH, CH=CH₂, CH₂F or azidomethyl;

R¹⁶ is H or R³; and

X is $-(CH_2)_m(O)_n(CH_2)_mN(R^{10})_2$ wherein m is 0-2, n is 0-1, and R^{10} independently is

H,

5 C₁-C₁₅ alkyl, C₂-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₆-C₁₅ arylalkynyl, C₂-C₁₅ alkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroaralkyl, C₅-C₆ aryl, C₂-C₆ heterocycloalkyl,

10 C₂-C₁₅ alkyl, C₃-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₃-C₁₅ alkynyl, C₇-C₁₅ arylalkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroalkyl or C₃-C₆ heterocycloalkyl wherein methylene in the alkyl moiety not adjacent to N⁶ has been replaced by -O-,


optionally both R^{10} are joined together with N to form a saturated or unsaturated C₂-C₅ heterocycle containing one or two N heteroatoms and optionally an additional O or S heteroatom,

15 or one of the foregoing R^{10} groups which is substituted with 1 to 3 halo, CN or N₃; but one or two R^{10} groups are not H; and

Z is N or CH, provided that the heterocyclic nucleus varies from purine by no more than one Z; and the therapeutically acceptable salts thereof.

20 Unexpectedly and surprisingly, N⁶ substitution of adenine or diaminopurine results in the acquisition of extremely high potency against DNA viruses on the part of the defined compounds. Such compounds otherwise have been considered to have little or no activity against DNA viruses. Moreover, surprisingly the chirally enriched or pure (S) enantiomer is antivirally active. Heretofore, only the (R) enantiomer was notably antivirally active, and then only against the retroviruses.

25 Also provided in accordance with this invention are novel compounds having structure (2)



wherein

30 Y independently is, OH, -OR³, -OCH(R¹⁶)OC(O)R³, a monophosphate, a diphosphate, an amino acid amidate, a polypeptide amidate, -NHR³, or -N(R³);

X is $-(CH_2)_m(O)_n(CH_2)_mN(R^{10})_2$ wherein m is 0-2, n is 0-1;


Z is N or CH, provided that the heterocyclic nucleus varies from purine by no more than one Z;

R^3 independently is unsubstituted alkyl, aryl, alkenyl, alkynyl, alkaryl, alkynylaryl or alkenylaryl; R^3 is substituted by C₁-C₆ alkoxy, C₁-C₆


5 carboxylalkylester, halo, carboxy, hydroxyl, cyano, nitro, N-morpholino, or amino; and/or R^3 wherein -CH₂- has been substituted by NH, S, or O;

$R^{2'}$ and R^2 independently are halo, NH₂, X or H, but at least one R^2 is X;


E is -(CH₂)₂-, -CH(CH₃)CH₂-, -CH(CH₂F)CH₂-, -CH(CH₂OH)CH₂-,
-CH(CH=CH₂)CH₂-, -CH(C≡CH)CH₂-, -CH(CH₂N₃)CH₂-,



(3)



(4)



(5)

10

-CH(R⁶)OCH(R^{6'})-, -CH(R⁹)CH₂O- or -CH(R⁸)O-, wherein the right hand bond is linked to the 9 position of the purine, monoazapurine or monodeazapurine heterocycle and wherein Y and the hydroxyl group of -CH(CH₂OH)CH₂-, R⁴, R⁶, R⁸, or R⁹ are joined to form a 6 membered ring;

15

the broken line represents an optional double bond;

R^4 and R^5 are independently hydrogen, hydroxy, halo, amino or a substituent having 1-5 carbon atoms selected from acyloxy, alkoxy, alkylthio, alkylamino and dialkylamino;

20

R^6 and $R^{6'}$ are independently H, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl, or C₂-C₇ alkanoyl;

R^7 are independently are H, C₁-C₆ alkyl, or are taken together to form -O- or -CH₂-;

R^8 is H, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl or C₁-C₆ haloalkyl;

R^9 is H, hydroxymethyl or acyloxymethyl; and

25

R^{10} independently is

H,

C₁-C₁₅ alkyl, C₂-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₆-C₁₅ arylalkynyl, C₂-C₁₅ alkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroaralkyl, C₅-C₆ aryl, C₂-C₆ heterocycloalkyl,

30

C₂-C₁₅ alkyl, C₃-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₃-C₁₅ alkynyl, C₇-C₁₅ arylalkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroalkyl or C₃-C₆ heterocycloalkyl wherein methylene in the alkyl moiety not adjacent to N⁶ has been replaced by -O-.

- optionally both R^{10} are joined together with N to form a saturated or unsaturated C_2 - C_5 heterocycle containing one or two N heteroatoms and optionally an additional O or S heteroatom, or one of the foregoing R^{10} groups which is substituted with 1 to 3 halo, CN or N_3 ; but one or two R^{10} groups are not H; R^{16} is H or R^3 ; and the therapeutically acceptable salts thereof; provided, however, that
- (a) when E is $-CH(CH_3)CH_2-$ and R^2 is NH_2 , then X is not dimethylamino, cyclopropylamino, cyclopentylamino, cyclohexylamino, pyrrolidinoamino, piperidinoamino, morpholinoamino or benzylamino;
- (b) when E is $-CH(CH_2OH)CH_2-$ and R^2 is H, then X is not dimethylamino, N-methyl-N-ethylamino or diethylamino; and
- (c) when E is $-(CH_2)_2-$ and R^2 is NH_2 , then X is not C_5 - C_7 cycloalkylamino or dimethylamino.

Detailed Description of the Invention

As used herein, and unless modified by the immediate context:

1. Alkyl means C_1 - C_{15} branched, normal or cyclic saturated hydrocarbons and includes methyl, ethyl, propyl, cyclopropyl, cyclobutyl, isopropyl, n-, sec-, iso- and tert-butyl, pentyl, isopentyl, 1-methylbutyl, 1-ethylpropyl, neopentyl, and t-pentyl.
2. Alkenyl means C_2 - C_{15} branched, normal or cyclic hydrocarbons containing at least 1 (generally 1-3) cis or trans oriented conjugated or unconjugated double bond, including allyl, ethenyl, propenyl, isopropenyl, 1-, 2- and 3-butenyl, 1- and 2-isobutenyl and the like.
3. Alkynyl means C_2 - C_{15} branched, normal, or cyclic hydrocarbon bearing at least 1 (generally 1-3) triple bond, e.g., 2-propynyl.
4. Aryl or heteroaryl means a resonant cyclic or fused polycyclic ring structure containing at least one 3-6 membered ring containing ring atoms solely of carbon or of carbon and one or two N-, S- or O- heteroatoms, including for example phenyl, 2- and 4-imidazolyl, 2-, 4- and 5-oxazolyl, 2-, 3-, 4- or 5-isoxazolyl, 2-, 3-, 4- or 5-furazanyl, 2-, 4- and 5-thiazolyl, 3-, 4- and 5-isothiazolyl, 3- and 4-pyrazolyl, 2-, 3- and 4-pyridinyl or 2-, 4- and 5-pyrimidinyl, 1-, 2-, 3- or 4- azetidine, 2-, 3-, 4-, or 5-thiophene, 2-, 3-, 4-, or 5-furanyl, 1-, 2-, 3-, 4-, or 5-pyrrolyl and analogues thereof in which a double bond has been shifted, e.g. 2H --pyrrole, or has been saturated, e.g. 2-pyrrolinyl or 3-pyrazolinyl. In general, while the foregoing are examples, any ring atom

other than oxygen or nitrogen serves as the binding site for the N⁶ amino group, although a ring nitrogen also is directly bonded to the 6-carbon of the purine in circumstances when two R¹⁰ are taken together.

5 5. Alkaryl, alkenylaryl, alkynylaryl, arylalkyl, arylalkynyl, or aralkenyl means alkyl, alkynyl or alkenyl substituted with at least 1 (generally 1-3) aryl groups, or aryl substituted with at least 1 (generally 1-3) alkyl, alkynyl or alkenyl groups. When these are an R¹⁰ group they are bonded through an aliphatic (saturated or unsaturated) or aryl carbon to N⁶.


10 6. Heterocycloalkyl means any fully saturated alkyl group forming a ring having C₃-C₆ in which 1 to 3 CH₂ groups have been substituted with NH, O or S. Ordinarily, only 1 or 2 methylene groups are substituted by a heteroatom. Heterocycloalkyl includes the saturated counterparts of the heteroaryl groups defined above, and includes for example piperazinyl, morpholino, aziridinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 15 piperidinyl, tetrahydrofuranyl. As in the case with the unsaturated heterocycles described above, any ring atom other than oxygen or nitrogen serves as the binding site for the N⁶ amino group, although a ring nitrogen also is directly bonded to the 6-carbon of the purine in circumstances when two R¹⁰ are taken together.

20 R¹ typically is CH₃.


 R² and R^{2'} are usually X, H or NH₂, but at least one of R^{2'} or R² is X. In some embodiments, both of R^{2'} and R² are X, which then may be the same or different, but in general only 1 R² or R^{2'} is X. Embodiments include the following R² and R^{2'} substitutions, respectively: H, X; NH₂, X; X, X; X, H; X, 25 NH₂. Ordinarily, X is found at the 6 position and the 2-position is substituted with NH₂ or H. R² or R^{2'} also are halo such as chloro or bromo, whereupon in some embodiments the other R² or R^{2'} is X. The halo compounds are particularly useful as intermediates. R² generally is H where the compounds herein are to be employed for the treatment or prophylaxis of DNA virus 30 infections, but compounds in which R² is NH₂ are satisfactory.

 R³ is not a critical functionality and may vary widely. R³ for example includes C₃-C₆ aryl (including phenyl, 2- and 3-pyrrolyl, 2- and 3-thienyl, 2- and 4-imidazolyl, 2-, 4- and 5-oxazolyl, 3- and 4-isoxazolyl, 2-, 4- and 5-thiazolyl, 3-, 4- and 5-isothiazolyl, 3- and 4-pyrazolyl, 1-, 2-, 3- and 4-pyridinyl, 35 and 1-, 2-, 4- and 5-pyrimidinyl), C₃-C₆ aryl substituted with halo, alkyl C₁-C₁₂ alkoxy, CN, NO₂, OH, carboxy, carboxyester, thiol, thiolester, C₁-C₁₂ haloalkyl (1-6 halogen atoms), C₂-C₁₂ alkenyl or C₂-C₁₂ alkynyl (including 2-, 3- and 4-alkoxyphenyl (C₁-C₁₂ alkyl), 2-, 3- and 4-methoxyphenyl, 2-, 3- and 4-

- ethoxyphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-diethoxyphenyl, 2- and 3-carboethoxy-4-hydroxyphenyl, 2- and 3-ethoxy-4-hydroxyphenyl, 2- and 3-ethoxy-5-hydroxyphenyl, 2- and 3-ethoxy-6-hydroxyphenyl, 2-, 3- and 4-O-acetylphenyl, 2-, 3- and 4-dimethylaminophenyl, 2-, 3- and 4-
- 5 methylmercaptophenyl, 2-, 3- and 4-halophenyl (including 2-, 3- and 4-fluorophenyl and 2-, 3- and 4-chlorophenyl), 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dimethylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-biscarboxyethylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dimethoxyphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dihalophenyl (including 2,4-difluorophenyl and 3,5-difluorophenyl), 2-, 3- and
- 10 4-haloalkylphenyl (1 to 5 halogen atoms, C₁-C₁₂ alkyl including 4-trifluoromethylphenyl), 2-, 3- and 4-cyanophenyl, 2-, 3- and 4-nitrophenyl, 2-, 3- and 4-haloalkylbenzyl (1 to 5 halogen atoms, C₁-C₁₂ alkyl including 4-trifluoromethylbenzyl and 2-, 3- and 4-trichloromethylphenyl and 2-, 3- and 4-trichloromethylphenyl), 4-N-methylpiperidiny, 3-N-methylpiperidiny, 1-
- 15 ethylpiperazinyl, benzyl, -C₆H₄-C(O)-O alkyl C₁-C₅, (C₁-C₄ alkyl, including 2-, 3- and 4-ethylsalicylphenyl), 2,3- and 4-acetylphenyl, 1,8-dihydroxynaphthyl (-O-C₁₀H₆-OH) and aryloxyethyl [C₆-C₉ aryl (including phenoxyethyl)], 2,2'-dihydroxybiphenyl, alkoxylethyl [C₁-C₆ alkyl including -CH₂-CH₂-O-CH₃ (2-methoxyethyl)], alkyl substituted by OH or by 1 to 3 halo atoms (including -CH₃,
- 20 -CH(CH₃)₂, -C(CH₃)₃, -CH₂CH₃, -(CH₂)₂CH₃, -(CH₂)₃CH₃, -(CH₂)₄CH₃, -(CH₂)₅CH₃, -CH₂CH₂F, -CH₂CH₂Cl, -CH₂CF₃, and -CH₂CCl₃), 2-, 3- and 4-N,N-



- dialkylaminophenyl, -C₆H₄CH₂-N(CH₃)₂, ; -N-2-propylmorpholino, 2,3-dihydro-6-hydroxyindene, sesamol, catechol monoester, -CH₂-C(O)-N(R¹¹)₂ wherein each R¹¹ is the same or different H or
- 25 C₁-C₄ alkyl, -CH₂-S(O)(R¹¹), -CH₂-S(O)₂(R¹¹), -CH₂-CH(OC(O)CH₂R¹¹)-CH₂(OC(O)CH₂R¹¹),olesteryl, a 5 or 6 carbon monosaccharide, disaccharide or oligosaccharide (3 to 9 monosaccharide residues), enolpyruvate (HOOC-C(=CH₂)O), glycerol, α-D-β-diglycerides (wherein the fatty acids composing glyceride lipids generally are naturally occurring saturated or unsaturated C₆-26,
- 30 C₆-18 or C₆-10 fatty acids such as linoleic, lauric, myristic, palmitic, stearic, oleic, palmitoleic, linolenic and the like fatty acids), trimethoxybenzyl, triethoxybenzyl, 2-alkylpyridinyl (C₁₋₄ alkyl),



C₁-C₄ alkylene-C₃-C₆ aryl (including benzyl, -CH₂-pyrrolyl, -CH₂-thienyl, -CH₂-imidazolyl, -CH₂-oxazolyl, -CH₂-isoxazolyl, -CH₂-thiazolyl, -CH₂-isothiazolyl, -CH₂-pyrazolyl, -CH₂-pyridinyl and -CH₂-pyrimidinyl) substituted in the aryl moiety by 3 to 5 halogen atoms or 1 to 2 atoms or groups selected from halogen,
5 C₁-C₁₂ alkoxy (including methoxy and ethoxy), cyano, nitro, OH, C₁-C₁₂ haloalkyl (1 to 6 halogen atoms; including -CH₂-CCl₃), C₁-C₁₂ alkyl (including methyl and ethyl), C₂-C₁₂ alkenyl or C₂-C₁₂ alkynyl, and other compounds set forth in Table 1a below. The hydroxyl groups of the compounds herein optionally are substituted with one of groups III, IV or V disclosed in
10 WO94/21604.

R⁴ and R⁵ typically are H, halo or OH, preferably H.

R⁶ and R^{6'} generally are H or methyl. Usually, R⁶ is H or methyl while R^{6'} is H.

R⁷ usually is H.

15 R⁸ and R⁹ typically are H, methyl or hydroxymethyl.

R¹⁰ groups are an important functionality. They are responsible for the unexpected development of anti-DNA virus activity in the PMP series. One or both of these groups is other than H.

Typically, the R¹⁰ groups are relatively small, on the order of 1 to 6 carbon atoms and 0 to 1 N and optionally an S or O atom in total for each R¹⁰.
20 When both R¹⁰ are not hydrogen, one R¹⁰ is optionally smaller than the other, e.g. one may contain 2-6 carbon atoms, and the other only 1.


Ordinarily the heteroatoms present in R¹⁰ are not terminally located and are substituted for CH₂ or CH. In some embodiments the heteroatom is
25 donated by the 6-amino group of the heterocyclic base, as occurs when two R¹⁰ groups are cyclized to form a ring. In such cases, the N is bonded to the 6 carbon of the purine. However, it is not necessary that a heterocyclic alkyl or aryl that contains a ring N atom be bonded to C-6 via the N atom. It is also within the scope of this invention to bond such groups through ring carbon
30 atoms directly or through intervening alkyl or alkoxyalkyl groups. Such intervening linking groups generally will be small (C₁-C₄), such as methylene, ethylene or ethoxy.

Ordinarily, R¹⁰ is C₁-C₆ alkyl; C₃-C₆ cycloalkyl; C₃-C₄ cycloalkyl-substituted C₁-C₂ alkyl; C₃-C₄ cycloalkyl which is mono-, di- or tri-substituted
35 with C₁-C₃ alkyl; -CH(Phe)₂; allyl; or allyl wherein H atoms are substituted with C₁-C₃ alkyl groups.

A particularly interesting embodiment is R¹⁰ alkyl, alkene or alkyne which further contains intrachain N and/or O atoms, wherein one intrachain

- N atom may be acidic (NH) or substituted with alkyl, typically C₁-C₅. Generally such R¹⁰ groups will terminate in a single N(alk)₂ group wherein alk is alkyl as defined herein. Such R¹⁰ groups usually are paired with an R¹⁰ = H or C₁-C₄ alkyl. Intrachain O or NH is used in any of the alkyl groups described
- 5 herein, where the heteroatoms are used to substitute CH₂. Typical R¹⁰ structures include -(CH₂)₂N(CH₃)(CH₂CH₃), (CH₂)₂N(CH₃)₂, (CH₂)₃N(CH₃)₂, -CH₂NHCH₂CH₂OCH₂NH(CH₃)₂, -CH₂NHCH₂OCH₂N(CH₃)₂,
 -CH₂◁, -CH(CH₃)◁, -(CH₂)₂OCH₂◁, ◁, ◇, -CH(CH₃)₂, -CH₂CH=CH₂,
 -CH=CH₂, -CH(CH₃)(CH=CH₂), -(CH₂)₂OCH₃, -(CH₂)₂OCH(CH₃)₂, -(CH₂)₂N ◁,
 -(CH₂)₂N ◻, -(CH₂)₂N ◻, -(CH₂)₂N ◁, -CH₂CH=CHPh, -CH₂CH=CHCH₃

and -CH₂C≡CH. Structures in which two R¹⁰ are joined together include



- Hydrogen atoms of R¹⁰ groups, particularly those described in the
- 10 preceding two paragraphs, and especially alkyl or alkene, in turn are optionally substituted with 1 to 3 of any of halogen (especially F), cyano or azido, or combinations thereof. Typical embodiments include -CH₂F, -CH₂CN, -(CH₂)₂N₃, -(CH₂)₂CH₂F, -CH₂N₃, -CH₂(fluorocyclopropyl), -CHFCH₃ or -(CH₂)₂NH(CH₃)(CH₂F).

- 15 In some embodiments when one R² is NH₂ then R¹⁰ is C₁-C₆-alkylamino-C₁-C₆-alkylamino or pyrrolidino, but preferably the first.

R¹⁰ groups may bear chiral N or C atoms. These are suitably used as the racemic or diastereomeric mixtures, or they may be chirally pure. In general, it is preferred that they be chirally pure.

- 20 Z usually is selected in order to produce a purine nucleus, although optionally it is chosen in order to yield an aza or deaza (monoaza or monodeaza) purine nucleus such as 1-deaza, 3-deaza, 8-aza or 7-deaza.


- E generally is not an acetal (structure (5) or -CH(R⁶)OCH(R^{6'})-). Typically, E is -(CH₂)₂-, -CH(CH₃)CH₂-, -CH(CH₂OH)CH₂-, -CH(CH=CH₂)CH₂-,
 25 -CH(C≡CH)CH₂-, -CH(CH₂N₃)CH₂-, -CH(R⁹)CH₂O- or -CH(R⁸)O-, most ordinarily, -(CH₂)₂-, -CH(CH₃)CH₂- or -CH(CH₂OH)CH₂-.

The chiral carbon atom(s) in the various E groups are diastereomers or racemates, or they optionally are enantiomerically pure or enriched. In general, one will select the enantiomers or diastereomers that have been found

to be the most active in the parental compounds, e.g. the HPMP compound will be the (S) enantiomer, while the PMP compound will be the (R) enantiomer.

Group Y typically will be OH or convertible to OH by chemical or biological means. For *in vivo* hydrolysis Y usually is OR^3 in which R^3 is described above or Y is $-OCH(R^{16})OC(O)R^3$ or $-OCH(R^{16})OC(O)OR^3$. Y is OPRT in intermediates for the most part. Certain end uses for intermediate compounds of the invention contemplate Y = an oligonucleotide or protein. PRT is a conventional hydroxyl protecting group, e.g. see Greene et al., (*infra*) at pp. 10-142.

Particularly useful Y groups are alkylacyloxymethyl groups and their derivatives, including $-CH(CH_2CH_2OCH_3)OC(O)C(CH_3)_3$,



; $-CH_2OC(O)C_{10}H_{15}$, $-CH_2OC(O)C(CH_3)_3$,
 $-CH(CH_2OCH_3)OC(O)C(CH_3)_3$, $-CH(CH(CH_3)_2)OC(O)C(CH_3)_3$,
 $-CH_2OC(O)CH_2CH(CH_3)_2$, $-CH_2OC(O)C_6H_{11}$, $-CH_2OC(O)C_6H_5$,
 $-CH_2OC(O)C_{10}H_{15}$, $-CH_2OC(O)CH_2CH_3$, $-CH_2OC(O)CH(CH_3)_2$,
 $-CH_2OC(O)C(CH_3)_3$ and $-CH_2OC(O)CH_2C_6H_5$.

The use of amino protecting groups may be necessary during synthesis of the compounds of this invention, e.g. to protect an R^2 NH_2 group as required. R^{10} may or may not be an amino protecting group that may have been used or would have been expected to be useful in known synthetic methods for the parental compounds herein. Amino protecting groups are described in Greene et al. "Protective Groups in Organic Synthesis" pp. 315-385 (1991) and include Carbamates (methyl and ethyl, 9-fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7-di-*t*-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl, 4-methoxyphenacyl); Substituted Ethyl (2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1-(4-biphenyl)ethyl, 1-(3,5-di-*t*-butylphenyl)-1-methylethyl, 2-(2'- and 4'-pyridyl)ethyl, 2-(*N,N*-dicyclohexylcarboxamido)ethyl, *t*-butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, *N*-hydroxypiperidinyl, alkylidithio, benzyl, *p*-methoxybenzyl, *p*-nitrobenzyl, *p*-bromobenzyl, *p*-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9-anthrylmethyl, diphenylmethyl); Groups With Assisted Cleavage such as (2-methylthioethyl,

- 2-methylsulfonyl ethyl, 2-(*p*-toluenesulfonyl)ethyl, [2-(1,3-dithianyl)]methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2-triphenylphosphonioisopropyl, 1,1-dimethyl-2-cyanoethyl, *m*-chloro-*p*-acyloxybenzyl, *p*-(dihydroxyboryl)benzyl, 5-benzisoxazolylmethyl, or 2-
- 5 (trifluoromethyl)-6-chromonylmethyl; Groups Capable of Photolytic Cleavage, e.g., (*m*-nitrophenyl, 3,5-dimethoxybenzyl, *o*-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, phenyl(*o*-nitrophenyl)methyl); Urea-Type Derivatives (phenothiazinyl-(10)-carbonyl, *N'*-*p*-toluenesulfonylaminocarbonyl, *N'*-phenylaminothiocarbonyl); Miscellaneous Carbamates (*t*-amyl, *S*-benzyl
- 10 thiocarbamate, *p*-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropylmethyl, *p*-decyloxybenzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, *o*-(*N,N*-dimethylcarboxamido)benzyl, 1,1-dimethyl-3-(*N,N*-dimethylcarboxamido)propyl, 1,1-dimethylpropynyl, di(2-pyridyl)methyl, 2-furanylmethyl, 2-Iodoethyl, Isobornyl, Isobutyl, Isonicotinyl, *p*-(*p'*-
- 15 Methoxyphenylazo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl, 1-methyl-1-(*p*-phenylazophenyl)ethyl, 1-methyl-1-phenylethyl, 1-methyl-1-(4-pyridyl)ethyl, phenyl, *p*-(phenylazo)benzyl, 2,4,6-tri-*t*-butylphenyl, 4-(trimethylammonium)benzyl, 2,4,6-trimethylbenzyl); Amides (*N*-formyl, *N*-
- 20 acetyl, *N*-chloroacetyl, *N*-trichloroacetyl, *N*-trifluoroacetyl, *N*-phenylacetyl, *N*-3-phenylpropionyl, *N*-picolinoyl, *N*-3-pyridylcarboxamide, *N*-benzoylphenylalanyl, *N*-benzoyl, *N*-*p*-phenylbenzoyl); Amides With Assisted Cleavage (*N*-*o*-nitrophenylacetyl, *N*-*o*-nitrophenoxycetyl, *N*-acetoacetyl, (*N'*-dithiobenzyloxycarbonylamino)acetyl, *N*-3-(*p*-hydroxyphenyl)propionyl, *N*-3-
- 25 (*o*-nitrophenyl)propionyl, *N*-2-methyl-2-(*o*-nitrophenoxycetyl)propionyl, *N*-2-methyl-2-(*o*-phenylazophenoxy)propionyl, *N*-4-chlorobutyryl, *N*-3-methyl-3-nitrobutyryl, *N*-*o*-nitrocinnamoyl, *N*-acetylmethionine, *N*-*o*-nitrobenzoyl, *N*-*o*-(benzoyloxymethyl)benzoyl, 4,5-diphenyl-3-oxazolin-2-one); Cyclic Imide Derivatives (*N*-phthalimide, *N*-dithiasuccinoyl, *N*-2,3-diphenylmaleoyl, *N*-2,5-
- 30 dimethylpyrrolyl, *N*-1,1,4,4-tetramethyldisilylazacyclopentane adduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridonyl); *N*-Alkyl and *N*-Aryl Amines (*N*-methyl, *N*-allyl, *N*-[2-(trimethylsilyl)ethoxy]methyl, *N*-3-acetoxypentyl, *N*-(1-isopropyl-4-nitro-2-oxo-
- 35 3-pyrrolin-3-yl), Quaternary Ammonium Salts, *N*-benzyl, *N*-di(4-methoxyphenyl)methyl, *N*-5-dibenzosuberyl, *N*-triphenylmethyl, *N*-(4-methoxyphenyl)diphenylmethyl, *N*-9-phenylfluorenyl, *N*-2,7-dichloro-9-fluorenylmethylene, *N*-ferrocenylmethyl, *N*-2-picolylamine *N'*-oxide), Imine

Derivatives (*N*-1,1-dimethylthiomethylene, *N*-benzylidene, *N*-*p*-methoxybenzylidene, *N*-diphenylmethylene, *N*-[(2-pyridyl)mesityl]methylene, *N*,(*N'*,*N'*-dimethylaminomethylene, *N*,*N'*-isopropylidene, *N*-*p*-nitrobenzylidene, *N*-salicylidene, *N*-5-chlorosalicylidene, *N*-(5-chloro-2-hydroxyphenyl)phenylmethylene, *N*-cyclohexylidene); Enamine Derivatives (*N*-(5,5-dimethyl-3-oxo-1-cyclohexenyl)); *N*-Metal Derivatives (*N*-borane derivatives, *N*-diphenylborinic acid derivatives, *N*-[phenyl(pentacarbonylchromium- or -tungsten)]carbenyl, *N*-copper or *N*-zinc chelate); *N*-N Derivatives (*N*-nitro, *N*-nitroso, *N*-oxide); *N*-P Derivatives (*N*-diphenylphosphinyl, *N*-dimethylthiophosphinyl, *N*-diphenylthiophosphinyl, *N*-dialkyl phosphoryl, *N*-dibenzyl phosphoryl, *N*-diphenyl phosphoryl); *N*-Si Derivatives; *N*-S Derivatives; *N*-Sulfonyl Derivatives (*N*-benzenesulfonyl, *N*-*o*-nitrobenzenesulfonyl, *N*-2,4-dinitrobenzenesulfonyl, *N*-pentachlorobenzenesulfonyl, *N*-2-nitro-4-methoxybenzenesulfonyl, *N*-triphenylmethylsulfonyl, *N*-3-nitropyridinesulfonyl); and *N*-sulfonyl Derivatives (*N*-*p*-toluenesulfonyl, *N*-benzenesulfonyl, *N*-2,3,6-trimethyl-4-methoxybenzenesulfonyl, *N*-2,4,6-trimethoxybenzenesulfonyl, *N*-2,6-dimethyl-4-methoxybenzenesulfonyl, *N*-pentamethylbenzenesulfonyl, *N*-2,3,5,6-tetramethyl-4-methoxybenzenesulfonyl, *N*-4-methoxybenzenesulfonyl, *N*-2,4,6-trimethylbenzenesulfonyl, *N*-2,6-dimethoxy-4-methylbenzenesulfonyl, *N*-2,2,5,7,8-pentamethylchroman-6-sulfonyl, *N*-methanesulfonyl, *N*- β -trimethylsilyethanesulfonyl, *N*-9-anthracenesulfonyl, *N*-4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonyl, *N*-benzylsulfonyl, *N*-trifluoromethylsulfonyl, *N*-phenacylsulfonyl), and especially carbamates and amides, still more typically, -NHC(O)R³ or -N=CR⁴N(R³)₂.

In one embodiment of the compound of structure (1), R¹ is CH₃, Y is OH or OR³, R² is H, R^{2'} is X, and X is any one of -NH(CH₃)(CH₂CH₃), -NH(CH₂CH₃)₂, -NHCH₂CH=CH₂, -NH(CH₂)₂CH=CH₂, -NH(cyclopropyl), -NH(CH₂)₂NH(CH₃)₂, -NH(CH₂)₃NH(CH₃)₂, -NH(CH₂)₂NH(CH₃)(CH₂CH₃), -NH(CH₂)₃NH(CH₃)(CH₂CH₃), -NH(CH₂)₂NH(cyclopropyl), -NH(CH₂)₃NH(cyclopropyl), -NH(CH₂)₂NHCH₂(cyclopropyl), -NH(CH₂)₃NHCH₂(cyclopropyl), -NH(CH₂)₂NHCH₂CH=CH₂, -NH(CH₂)₃NHCH₂CH=CH₂, -NHCH₂C \equiv CH or -NHCH₂CH=CH(Phe).

In an embodiment of compounds of structure (2), E is -(CH₂)₂-, Y is OH or OR³, R² is NH₂, R^{2'} is X and X is any one of -NH(CH₃)(CH₂CH₃), -NH(CH₂CH₃)₂, -NHCH₂CH=CH₂, -NH(CH₂)₂CH=CH₂, -NH(cyclopropyl), -NH(CH₂)₂NH(CH₃)₂, -NH(CH₂)₃NH(CH₃)₂, -NH(CH₂)₂NH(CH₃)(CH₂CH₃), -NH(CH₂)₃NH(CH₃)(CH₂CH₃), -NH(CH₂)₂NH(cyclopropyl),

-NH(CH₂)₃NH(cyclopropyl), -NH(CH₂)₂NHCH₂(cyclopropyl),
 -NH(CH₂)₃NHCH₂(cyclopropyl), -NH(CH₂)₂NHCH₂CH=CH₂,
 -NH(CH₂)₃NHCH₂CH=CH₂, -NHCH₂C≡CH or -NHCH₂CH=CH(Phe).

In another embodiment of compounds of structure (2), E is

- 5 -CH(CH₂OH)CH₂-, Y is OH or OR³, R² is H, R^{2'} is X and X is any one of
 -NH(CH₃)(CH₂CH₃), -NH(CH₂CH₃)₂, -NHCH₂CH=CH₂, -NH(CH₂)₂CH=CH₂,
 -NH(cyclopropyl), -NH(CH₂)₂NH(CH₃)₂, -NH(CH₂)₃NH(CH₃)₂,
 -NH(CH₂)₂NH(CH₃)(CH₂CH₃), -NH(CH₂)₃NH(CH₃)(CH₂CH₃),
 -NH(CH₂)₂NH(cyclopropyl), -NH(CH₂)₃NH(cyclopropyl),
 10 -NH(CH₂)₂NHCH₂(cyclopropyl), -NH(CH₂)₃NHCH₂(cyclopropyl),
 -NH(CH₂)₂NHCH₂CH=CH₂, -NH(CH₂)₃NHCH₂CH=CH₂, -NHCH₂C≡CH or
 -NHCH₂CH=CH(Phe).

In another embodiment of compounds of structure (1), R¹ is CH₃, Y is
 OH or OR³, R² is NH₂, R^{2'} is X and X is any one of -NH(CH₃)(CH₂CH₃),

- 15 -NH(CH₂CH₃)₂, -NHCH₂CH=CH₂, -NH(CH₂)₂CH=CH₂, -NH(cyclopropyl),
 -NH(CH₂)₂NH(CH₃)₂, -NH(CH₂)₃NH(CH₃)₂, -NH(CH₂)₂NH(CH₃)(CH₂CH₃),
 -NH(CH₂)₃NH(CH₃)(CH₂CH₃), -NH(CH₂)₂NH(cyclopropyl),
 -NH(CH₂)₃NH(cyclopropyl), -NH(CH₂)₂NHCH₂(cyclopropyl),
 -NH(CH₂)₃NHCH₂(cyclopropyl), -NH(CH₂)₂NHCH₂CH=CH₂,
 20 -NH(CH₂)₃NHCH₂CH=CH₂, -NHCH₂C≡CH or -NHCH₂CH=CH(Phe).

In an additional embodiment of compounds of structure (1), R¹ is CH₃,
 Y is OH or OR³, R² and R^{2'} are both X and X is independently selected from
 any one of -NH(CH₃)(CH₂CH₃), -NH(CH₂CH₃)₂, -NHCH₂CH=CH₂,

- NH(CH₂)₂CH=CH₂, -NH(cyclopropyl), -NH(CH₂)₂NH(CH₃)₂,
 25 -NH(CH₂)₃NH(CH₃)₂, -NH(CH₂)₂NH(CH₃)(CH₂CH₃),
 -NH(CH₂)₃NH(CH₃)(CH₂CH₃), -NH(CH₂)₂NH(cyclopropyl),
 -NH(CH₂)₃NH(cyclopropyl), -NH(CH₂)₂NHCH₂(cyclopropyl),
 -NH(CH₂)₃NHCH₂(cyclopropyl), -NH(CH₂)₂NHCH₂CH=CH₂,
 -NH(CH₂)₃NHCH₂CH=CH₂, -NHCH₂C≡CH or -NHCH₂CH=CH(Phe).

30

Utilities

The novel compounds of this invention are useful per se or as
 intermediates in the preparation of polymers having a wide variety of
 diagnostic, therapeutic and industrial utilities.

- 35 The compounds are useful in the preparation of polyphosphonate flame
 retardants. The compounds of this invention that contain nonresonant sites
 of unsaturation, e.g., which contain vinyl, allyl or other sites of aliphatic
 unsaturation, are incorporated into polyvinyl polymers by methods heretofore

employed to polymerize known vinylphosphonates, or methods clearly analogous thereto that will be apparent to the ordinary artisan. These monomers are copolymerized with vinyl resins by free radical catalysis methods already known per se, e.g., by use of persulfate or electron beam. The compounds of this invention that do not already contain vinyl groups are
5 useful nonetheless as intermediates preparing vinylphosphonate monomers, or may be polymerized using other methods.

The compounds of this invention are also suitable as intermediates for use in the preparation of affinity absorption matrices that harness the chemical
10 properties of the compounds' substituent groups. For example, the phosphonate groups in matrix bound form are useful in the chromatographic separation of positively charged molecules. Other immobilized examples of the compounds herein are useful in purifying proteins, e.g., enzymes involved in recognition of the compounds of this invention, e.g. transport proteins (see
15 Cihlar, supra). Suitable methods of incorporation of the compounds of this invention into polymeric resins will be readily apparent to the skilled artisan, for instance the compounds are incorporated by cross-linking hydroxyl groups of the phosphonate or hydroxymethyl substituents using cross-linking agents heretofore known. Linking through a group other than the heterocyclic base
20 will produce a resin useful in hydrophobic affinity chromatography. Other suitable linking methods are described in Cihlar (supra).

The compounds of this invention are useful as intermediates in preparing labeled oligonucleotide probes, e.g., where Y becomes an oligonucleotide. These oligonucleotides are directly useful in assays for target
25 nucleic acid sequences. Typically, the phosphonate group of the compounds of this invention is covalently bonded to the terminus of an oligonucleotide having a predetermined sequence, although any hydroxyl group of the compounds of the invention is useful for this purpose. The structure or sequence of the oligonucleotide is not important except insofar as it is binding-
30 competent for its complementary sequence. Many oligonucleotides having this property are well known, e.g. conventional phosphodiester or phosphorothioate oligonucleotides.

The compounds of this invention generally will be terminally incorporated into the oligonucleotide. If they contain a nonphosphonyl free
35 hydroxyl group, they optionally are incorporated internally into the sequence of the oligonucleotide. Terminally incorporated diphosphoryl compounds of this invention which contain no free hydroxyl capable of participating in chain elongation also are useful in DNA sequencing in essentially the same manner

as deoxyNTPs have been used in the past (see example 8 of U.S. Patent 5,276,143). The nucleotide analogues of the invention (when diphosphorylated) are useful as chain terminators for dideoxynucleotide-type DNA sequencing protocols, provided that the nucleotide analogue lacks a free
5 hydroxyl group suitable for polymerase mediated chain elongation. These compounds will not have R=hydroxymethyl and do not possess a cyclic structure incorporating the phosphorus atom (although compounds having such excluded structures can be intermediates). The nucleotide analogue is included in a kit with other reagents (such as Klenow polymerase or T4
10 polymerase, dNTPs, etc) needed for DNA sequencing (Otvos, et al, "Nucl. Acids Res." 15:1763-1777 (1987).

If the oligonucleotide-incorporated compound of this invention is binding-competent for its complementary sequence, i.e., if it is capable of base-pairing, then this nucleotide monomer will participate in hybridization. It is
15 not necessary, however, that the incorporated nucleotide analogue of this invention base pair or otherwise participate in hybridization. If it is located at the terminus of the oligonucleotide it will be useful as an immunological recognition site, or haptenic recognition site, to facilitate detection of the oligonucleotide by an antibody capable of binding the compound of this
20 invention.

The compounds of this invention also are useful as linkers or spacers in preparing affinity absorption matrices (as opposed to functioning as affinity moieties per se as noted above), immobilized enzymes for process control, or immunoassay reagents. The compounds herein contain a multiplicity of
25 functional groups that are suitable as sites for cross-linking desired substances. For example, it is conventional to link affinity reagents such as hormones, peptides, antibodies, drugs, and the like to insoluble substrates. These insolubilized reagents are employed in known fashion to absorb binding partners for the affinity reagents from manufactured preparations, diagnostic
30 samples and other impure mixtures. Similarly, immobilized enzymes are used to perform catalytic conversions with facile recovery of enzyme. Bifunctional compounds are commonly used to link analytes to detectable groups in preparing diagnostic reagents.

Many functional groups present in the compounds of this invention are
35 suitable for use in cross-linking. For example, the phosphonic acid is used to form esters with alcohols or amides with amines. The R groups substituted with OH, azido (which is reduced to amino if desired before cross-linking) or vinyl are exemplary suitable sites. Similarly, the amino, halo, acyl and other

reactive sites found on group B are suitable. Suitable protection of reactive groups will be used where necessary while assembling the cross-linked reagent. In general, the compounds here are used by linking them through phosphonic acid to the hydroxyl or amino groups of the linking partner in the same
5 fashion as shown herein, and covalently bonded to the other binding partner through an R group. For example a first binding partner such as a steroid hormone is esterified to the phosphonic acid of this invention and then this conjugate is cross-linked through hydroxymethyl R to cyanogen bromide activated Sepharose, whereby immobilized steroid is obtained. Other
10 chemistries for conjugation are well known. See for example Maggio, "Enzyme-Immunoassay" (CRC, 1988, pp 71-135) and references cited therein.

The oligonucleotides of this invention are labeled with any conventional detectable label, e.g. a fluorescent moiety such as fluorescein, radioisotopes such as C_{14} or H_3 , stable free radicals, avidin, biotin and the like
15 all of which previously have been used as labels for immunoassays or diagnostic probes. The label will be present on the oligonucleotide or on the residue of the nucleotide analogue of this invention. Suitable labeling methods are well known and are readily used with reactive groups such as hydroxyl, allyl and the like. A simple method is to label the compound of this
20 invention with H_3 by proton exchange. The compounds also are biotinylated using conventional methods. See for instance U.S. Patent 5,276,143 for analogous structures. However, the oligonucleotides of this invention also are useful directly in diagnostic probe assays without an exogenous detectable label. In one embodiment of this alternative, antibodies are raised against the
25 compounds of this invention. Such antibodies (which in turn are labelled or used in a double antibody configuration) bind to the analogue of this invention and thereby are useful in detecting its presence as label for a protein or oligonucleotide.

The compounds of the invention are useful for treatment of microbial
30 infections, for treatment of tumors or for other indications described below. Microbial infections treatable by the compounds of this invention include viruses, parasites, yeasts and fungi, but it is believed that the compounds are most effective against viruses, which constitutes the preferred utility. Exemplary viral infections include infections caused by DNA or RNA viruses
35 including herpesviruses (CMV, HSV 1, HSV 2, EBV, varicella zoster virus [VZV] (the novel compounds of structure (1) are exceptionally potent against this virus, and therefore will be useful in the treatment of shingles and chicken pox, ordinarily by topical application), bovid herpesvirus type 1, equid

herpesvirus type 1, HHV-6, papillomaviruses (HPV types 1-55 including carcinogenic HPV), flaviviruses (including yellow fever virus, African swine fever virus and Japanese encephalitis virus), togaviruses (including Venezuelan equine encephalomyelitis virus), influenza viruses (types A-C),
 5 retroviruses (HIV-1, HIV-2, HTLV-I, HTLV-II, SIV, FeLV, FIV, MoMSV), adenoviruses (types 1-8), poxviruses (vaccinia virus), enteroviruses (poliovirus types 1-3, Coxsackie, hepatitis A virus, and ECHO virus), gastroenteritis viruses (Norwalk viruses, rotaviruses), hantaviruses (Hantaan virus), polyomavirus, papovaviruses, rhinoviruses, parainfluenza virus types 1-4, rabies virus,
 10 respiratory syncytial virus (RSV), hepatitis viruses A, B, C and E, and the like.

The antiviral activity of individual nucleotide analogues is determined by routine assay of antiviral (or other antimicrobial) activity using enzyme inhibition assays, tissue culture assays, animal model assays and the like as will be understood by those skilled in the art.

15 Protozoan parasite infections are treated using the compounds of the invention. The term protozoa includes those members of the subphyla *Sarcomastigophora* and *Sporozoa* of the phylum *Protozoa*. More particularly, the term protozoa as used herein includes genera of parasitic protozoa which are important to man because they either cause disease in man or in his
 20 domestic animals. These genera for the most part are classified in the superclass *Mastigophora* of the subphylum *Sarcomastigophora* and the class *Telosporea* of the subphylum *Sporozoa* in the classification according to Baker (1969). Illustrative genera of these parasitic protozoa include *Histomonas*, *Pneumocystis*, *Trypanosoma*, *Giardia*, *Trichomonas*, *Eimeria*, *Isopora*,
 25 *Leishmania*, *Entamoeba*, *Toxoplasma* and *Plasmodium*. Parasitic protozoans include *Plasmodium falciparum*, *Plasmodium berghei*, *Plasmodium malariac*, *Plasmodium vivax*, *Leishmania braziliensis*, *Leishmania donovani*, *Trypanosoma cruzi*, *Trypanosoma brucei*, *Trypanosoma rhodesiense*, *Pneumocystis carinii*, *Entamoeba histolytica*, *Trichomonas vaginalis* and the
 30 like (de Vries, E., et al, "Mol. Biochem. Parasitol" 47:43-50 (1991)) and trypanosomes (Kaminsky et al. "J. Parasitol." 80(6):1026-30 (1994). The compounds in which R is CH₂OH and B is 3-deazaadenine are particularly interesting in the treatment of malarial parasites.

Nucleotide analogues of the invention are used to treat yeast or fungal
 35 infections caused by *Candida glabrata*, *Candida ropicalis*, *Candida albicans*, and other *Candida* species, *Cryptococcus* species including *Cryptococcus neoformans*, *Blastomyces* species including *Blastomyces dermatidis*,

Torulopsis species including *Torulopsis glabrata*, *Coccidioides* species including *Coccidioides immitis*, *Aspergillus* species and the like.

The therapeutically useful compounds of this invention are useful in oral or sustained release forms. In these uses an ester or other group is removed in vivo, e.g., hydrolyzed or oxidized, so as to yield for example a free amino or hydroxyl group. Suitable protecting or precursor esters or amidates are selected based on the substrate specificity of esterases and/or carboxypeptidases expected to be found within cells where precursor hydrolysis is desired. To the extent that the specificity of these enzymes is unknown, one will screen a plurality of nucleotide analogues of this invention until the desired substrate specificity is found. This will be apparent from the appearance of free phosphonate or of antimicrobial activity. One generally selects compounds that are (i) not hydrolyzed or hydrolyzed comparatively slowly in the upper gut, (ii) gut and cell permeable and (iii) hydrolyzed in the cell cytoplasm and/or systemic circulation. Screens with cells from particular tissues are used to identify precursors that are released in organs susceptible to a target viral or microbial infection, e.g. in the case of liver, precursor drugs capable of hydrolysis in the liver. Other infections, e.g. CMV or HIV, optionally are treated with a precursor that is hydrolyzed at substantially the same rate and to substantially the same degree in all tissues. Assays known in the art are suitable for these purposes, including intestinal lumen stability, cell permeation, liver homogenate stability and plasma stability assays. These assays are used to determine the bioavailability characteristics of the precursors. However, even if the derivatives are not converted in vivo they remain useful as chemical intermediates.

The nucleotide analogues of the invention also can be (1) applied to tissue culture systems to eliminate or reduce viral spread or growth during the production of biopharmaceuticals or other products (such as proteins or vaccines), (2) used to eliminate or reduce viral spread or growth in clinical samples (such as blood), and (3) used to stop growth of tissue culture or bacterial cells (using toxic amounts of compound) while leaving the cells to carry on with protein production.

The compounds herein have been found to suppress immunostimulation. Accordingly, they can suppress metabolic activities of T-lymphocytes stimulated by diverse agents, e.g. concavalin A; they principally will find application in the treatment of autoimmune diseases, e.g. arthritis, or in suppression of transplant rejection. Their therapeutically active concentrations are in the range of 5 mg/kg to 100 mg/kg of body weight.

Pharmaceutical formulations. Compounds herein and their physiologically acceptable salts (hereafter collectively referred to as the active ingredients) are formulated for administration by any route appropriate to the condition to be treated. The compounds and formulations preferably will be sterile.

The active ingredients are placed into pharmaceutical formulations. The formulations, both for veterinary and for human use, comprise at least one active ingredient, as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient.

The formulations conveniently are presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

For external infections of the eye or other external tissues e.g. mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc), typically 0.2 to 15% w/w and most typically 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base.

If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin

or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogues.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. This phase may comprise an emulsifier alone, or a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Emulsion stabilizers suitable for use in the formulation of the present invention include Tween[®] 60, Span[®] 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate. Suitable oils or fats include straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate or 2-ethylhexyl palmitate. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is typically present in such formulations in a concentration of 0.01 to 20% by weight.

Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc), which is administered by rapid inhalation through the nasal passage from a container of the powder. Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as pentamidine for treatment of pneumocystis pneumonia.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile
5 suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous
10 injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.

The present invention further provides veterinary compositions
15 comprising at least one active ingredient as above defined together with a veterinary carrier therefor. Veterinary carriers are materials for administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally,
20 parenterally or by any other desired route.

Compounds herein optionally are used in controlled release pharmaceutical formulations containing as active ingredient one or more active compounds in which the release of the active ingredient is controlled and regulated to allow less frequent dosing or to improve the pharmacokinetic
25 or toxicity profile of a given compound. In general, the compounds are administered from controlled release systems such as the intravitreal implant of WO 92/14450 or U.S. Patent 5,098,443, or the matrices of U.S. Patent 4,740,365 or U.S. Patent 5,141,752. Many others are known and are suitable for use herein.

30 Therapeutic Administration. Suitable routes for administration include oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravitreal, intravenous, intradermal, intrathecal and epidural). The preferred route of administration will depend upon the condition of the patient, the toxicity of
35 the compound and the site of infection, among other considerations known to the clinician.

For each of the above-indicated therapeutic indications the amount required of an active ingredient (as above defined) will depend upon a number

of factors including the severity of the condition to be treated, the infectious agent, whether the use is prophylactic or to treat an acute infection, the site of infection or pathology (e.g. CMV retinitis is treated systemically or by intravitreal injection, or in the treatment of HHV-6 in multiple sclerosis patients, optionally by intrathecal administration) and other factors ultimately at the discretion of the attending physician or veterinarian. In general, however, a suitable dose for consideration by the clinician will be in the range of analogous methoxyphosphonates (see supra), taking into account differences in potency, generally 0.1 to 250 mg per kilogram bodyweight of recipient per dose (including active ingredient(s) in a range between 0.1 mg and 250 mg/Kg/dose in increments of 0.5 mg/Kg/dose such as 2.5 mg/Kg/dose, 3.0 mg/Kg/dose, 3.5 mg/Kg/dose, etc), typically in the range 0.5 to 50 mg per kilogram body weight per dose and most usually in the range 1 to 15 mg per kilogram body weight per dose. Unless otherwise indicated all weights of active ingredient are calculated as compounds wherein Y is not a polymer.

The desired dose is administered at appropriate intervals in unit dosage forms, usually with a relatively higher induction dose and lower, less frequent maintenance doses. The compounds also are used prophylactically, for example, by administration on about from 1 to 7 days before viral infection. HPV tumors or growths and herpes lesions often are treated topically, either by local injection or by topical gels, ointments or the like.

Internally cyclized compounds generally are expected to have a higher oral bioavailability than the corresponding uncyclized nucleotide analogue and/or exhibit reduced toxicity when compared with the same dose of the corresponding uncyclized nucleotide analogue. In addition, the N⁶-substituted compounds per se possess lower toxicity and are more selective than the comparable guanine derivatives. Thus, doses will be adjusted accordingly.

The compounds of the invention optionally are employed in combination with other therapeutic agents for the treatment or prophylaxis of the infections or conditions indicated above. Examples of such further therapeutic agents include agents that are effective for the treatment or prophylaxis of viral, parasitic or bacterial infections or associated conditions or for treatment of tumors or related conditions. These include 3'-azido-3'-deoxythymidine (zidovudine, AZT), 2'-deoxy-3'-thiacytidine (3TC), 2',3'-dideoxy-2',3'-dideoxyadenosine (D4A), 2',3'-dideoxy-2',3'-dideoxythymidine (D4T), carbovir (carbocyclic 2',3'-dideoxy-2',3'-dideoxyguanosine), 3'-azido-2',3'-dideoxyuridine, 5-fluorothymidine, (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), 2-chloro-2'-deoxyadenosine, 2-

deoxycorformycin, 5-fluorouracil, 5-fluorouridine, 5-fluoro-2'-deoxyuridine, 5-trifluoromethyl-2'-deoxyuridine, 6-azauridine, 5-fluoroorotic acid, methotrexate, triacetyluridine, 1-(2'-deoxy-2'-fluoro-1- β -D-arabinosyl)-5-iodocytidine (FIAC), tetrahydroimidazo(4,5,1-jk)-(1,4)-benzodiazepin-2(1H)-thione (TIBO), 2'-nor-cyclicGMP, 6-methoxypurine arabinoside (ara-M), 6-methoxypurine arabinoside 2'-O-valerate, cytosine arabinoside (ara-C), 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine (ddC), 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxyinosine (ddI), acyclic nucleosides such as acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, acyclic nucleotides such as HPMPC, PMEA, PMEG, PMPA, PMPDAP, FPMMA, HPMMA and HPMPDAP, (2R, 5R)-9-[tetrahydro-5-(phosphonomethoxy)-2-furanyl]adenine, (2R, 5R)-1-[tetrahydro-5-(phosphonomethoxy)-2-furanyl]thymine, other antivirals including ribavirin (adenine arabinoside), 2-thio-6-azauridine, tubercidin, aurintricarboxylic acid, 3-deazaneoplanocin, neoplanocin, rimantidine, adamantine, and foscarnet (trisodium phosphonoformate), antibacterial agents including bactericidal fluoroquinolones (ciprofloxacin, pefloxacin and the like), aminoglycoside bactericidal antibiotics (streptomycin, gentamicin, amikacin and the like), β -lactamase inhibitors (cephalosporins, penicillins and the like), other antibacterials including tetracycline, isoniazid, rifampicin, cefoperazone, clathromycin and azithromycin, antiparasite or antifungal agents including pentamidine (1,5-bis(4'-aminophenoxy)pentane), 9-deazainosine, sulfamethoxazole, sulfadiazine, quinapyramine, quinine, fluconazole, ketoconazole, itraconazole, Amphotericin B, 5-fluorocytosine, clotrimazole, hexadecylphosphocholine and nystatin, renal excretion inhibitors such as probenecid, nucleoside transport inhibitors such as dipyridamole, dilazep and nitrobenzylthioinosine, immunomodulators such as FK506, cyclosporin A, thymosin α -1, cytokines including TNF and TGF- β , interferons including IFN- α , IFN- β and IFN- γ , interleukins including interleukin 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, macrophage/granulocyte colony stimulating factors including GM-CSF, G-CSF, M-CSF, cytokine antagonists including anti-TNF antibodies, anti-interleukin antibodies, soluble interleukin receptors, protein kinase C inhibitors and, particularly in treatment of HIV, cotherapy with IFN- α , IL-2 or IL-12.

Immunogens and Antibodies. The compounds of this invention are used as immunogens to prepare antibodies capable of binding specifically to the compounds or their metabolic products. The immunogenic compositions are useful as intermediates in the preparation of antibodies for use in diagnostic or quality control assays for the compounds or their metabolic products. The

antibodies are useful for measuring the presence, absence or amounts of the compounds by any convenient homogenous or heterogenous procedure such as fluorescence polarization immunoassay, fluorescence immunoassay (using fluorescent labels such as fluorescein and the like), radioimmunoassay, 5 enzyme immunoassay (using enzyme indicators such as alkaline phosphatase, horseradish peroxidase, glucose oxidase, urease and the like) and nephelometric inhibition assay by described methods (WO 92/22639). Competitive-type assays usually require the antibody, and a tracer (such as a fluorescent or radio label) conjugated to the compound to be assayed. The 10 antibodies directed against the compounds of this invention desirably will not cross-react with naturally-occurring nucleotides or nucleosides.

The immunogens of this invention contain the precursor or hydrolytic products in association with an immunogenic substance such as a protein or peptide. Immunogenic substances include adjuvants such as Freund's 15 adjuvant, immunogenic proteins such as viral, bacterial, yeast, plant and animal polypeptides, in particular keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin or soybean trypsin inhibitor, and immunogenic polysaccharides.

Methods for the manufacture of hapten immunogens are conventional 20 *per se*, and are useful here, taking into account the functional groups that are available for cross-linking. The polypeptide immunogen (or a polypeptide that is desired to be made immunogenic by cross-linking to a compound of this invention) may be conjugated to a site on the heterocyclic base rather than to the phosphonate moiety. In general, the site will be a phosphonyl hydroxyl 25 cross-linked by amidation or esterification of the phosphonate by the polypeptide itself or by a cross-linking functionality covalently bonded to the polypeptide, whereby Y is an immunogenic protein having more than 50 amino acid residues, usually less than 1000. The conjugates are prepared in conventional fashion. For example, N-hydroxysuccinimide, succinic 30 anhydride or N,N-disubstituted carbodiimides are useful in preparing the conjugates of this invention. Animals typically are immunized against the immunogenic conjugates and monoclonal antibodies prepared in conventional fashion.

35 Synthetic Methods

The compounds herein are prepared by methods known *per se*. See for example WO 94/03467 and WO 95/07920, or Schemes 1 and 2 below (note that any OH-alkylation protecting group can be used in place of isopropyl or R³, and


R³ and iPr can be used interchangeably). In general in Scheme 1, the 6-chloropurine is first alkylated in DMF either in the presence of an equivalent amount of sodium hydride or cesium carbonate at 60-100°C. The products are then isolated by silica chromatography and crystallized from ethyl acetate by
5 slow addition of petroleum ether until crystalization occurs (the 2-amino-6-chloropurinyl PME/PMP compounds are crystalline, but the 6-chloropurinyl PME/PMP compounds are oils). The obtained 6-chloro compound is treated in ethanol solution with an excess (5 to 10 times) of the corresponding amine under reflux. The reaction is followed by TLC or HPLC analysis. The mixture
10 is then evaporated, deionized on a cation exchanger column (Dowex 50), washed with 20% aqueous methanol, and the compound freed by the use of 2.5% ammonia in 20% aqueous methanol. The eluate is evaporated and dried over phosphorus pentoxide, the residue treated with 10% (v/v) bromotrimethylsilane in acetonitrile (5 ml per mM of compound) in order to
15 deprotect the hydroxyl groups. The mixture is allowed to stand overnight and worked up as described in WO 94/03467.

In an alternative method for making compounds of this invention, shown in Scheme 2, 6-chloropurine (R² = H or NH₂) is treated for 3-12 h with excess (5-10 fold) of primary or secondary amine in absolute ethanol or
20 methanol at reflux temperature or in an autoclave at 100-120°C. The solvent is taken down in vacuo and the residue codistilled with the same solvent. The residue is purified by crystallization, deionization on an cation exchange resin or by silica gel chromatography. The thus-obtained 6-(substituted amino)purine derivative (R² = H or NH₂) is pretreated in dimethylformamide
25 solution with one-half molar equivalent of cesium carbonate, one molar equivalent sodium hydride for 1 h at 100°C and the appropriate phosphoroorganic synthon used for example for the preparation of PME-, (R)-PMP or (S)-PMP-derivatives (1.1-1.5 molar equivalents is added to the mixture). The mixture is heated at 100-120°C for 8-16 h, stripped off the
30 solvent and the diester intermediate isolated by silica gel chromatography. The further treatment with bromotrimethylsilane and purification is performed as above.


It is not essential to employ the phosphonyl protecting group where it is expected that the N⁶ substituent may be labile to the TMS deprotection, e.g.
35 where R¹⁰ is an alkyl ether. In this case the free acid is used as the starting material for addition of the amine.

In the following Schemes, halogen, OMS, O-nitrobenzylsulfonyl, or O-triflyl are optionally used in place of OTs.

Scheme 1



Scheme 2



Phosphonoamidates, phosphonoesters and internally cyclized esters (where R =hydroxymethyl and a Y are taken together) are all prepared by methods analogous to those described in WO 95/07920 or other methods that will be apparent to the artisan.

Compounds of this invention where Y is an oligonucleotide are prepared from parental monomers in which Y is OH . The monomers are converted to the reactive intermediate using conventional chemistry, for example the method of Uhlmann et al., "Chemical Reviews" 90(4):543 at 553, part c and Fig. 23 (1990) or Mazur et al., "Tetrahedron Let." 40(20):3949 at scheme (1) and page 3955 (1984). For example, an oligonucleotide chain is synthesized on a matrix such as controlled pore glass in the 3'-5' or 5' to 3' direction, whereby the 3' or 5' ends, respectively of the oligonucleotide are bonded to the matrix and the oligonucleotide is protected except for the terminal 5' or 3' hydroxyl, respectively, of the last nucleotide. The protected o-

chlorophenyl derivative of the structure 1 compound is prepared, analogous to the starting material shown in Fig. 23 of Uhlmann et al. This is covalently bonded to a terminal OH of the oligonucleotide using the Uhlmann et al. method.

5 Alternatively, the compound of this invention is converted to the intermediate that is analogous to compound 12 of Mazur et al. This analogue is added to the oligonucleotide using essentially the dinucleotide preparative chemistry shown on page 3955 of Mazur et al. The pyridinium salt of the compound of this invention (without free hydroxyl groups) is condensed with
10 the free 5' or 3' end of the otherwise protected oligonucleotide in the same way Mazur et al. condense phosphonate 12 with a second nucleoside unit using DCC in dry pyridine in the presence of Dowex 50. After reaction by either method, the oligonucleotide is separated from the matrix (if present during the addition of the compound of this invention) and deprotected.

15 Alternatively, the compounds of this invention are chemically converted to nucleotide triphosphate analogues. This is accomplished using known reactions, for example reaction of the activated phosphonate (e.g. the morpholidate or imidazolidate with tris(tri-n-butylammonium) pyrophosphate in DMF.


20 Table 1 lists R³ ester and Y amidate moieties that can be bonded via oxygen or directly, respectively, to the phosphorus atom. Esters of structures 1-5, 8-10 and 16, 17, 19-22 are synthesized by reacting a nucleotide analogue having a free hydroxyl with the corresponding halide (chloride or acyl chloride and the like) and N,N-dicyclohexyl-N-morpholine carboxamidate (or another
25 base such as DBU, triethylamine, Cs₂CO₃, N,N-dimethylaniline and the like) in DMF (or other solvent such as acetonitrile or N-methylpyrrolidone). Esters of structures 5-7, 11, 12, 21, and 23-26 are synthesized by reaction of the alcohol or alkoxide salt (or the corresponding amines in the case of compounds such as 13, 14 and 15) with the monochlorophosphonate or dichlorophosphonate or
30 another activated phosphonate. These methods may not be optimal for the preparation of all esters, particularly those in which the ester linkage is sensitive, e.g. to hydrolysis. It may be desirable to prepare these from the free phosphonates or other diester intermediates such as hydroxyalkyl, aminoalkyl, etc.

35

TABLE 1

- | | | | |
|----|--|-----|---|
| 1. | $-\text{CH}_2-\text{C}(\text{O})-\text{N}(\text{R}^{15})_2^*$ | 10. | $-\text{CH}_2-\text{O}-\text{C}(\text{O})-\text{C}(\text{CH}_3)_3$ |
| 2. | $-\text{CH}_2-\text{S}(\text{O})(\text{R}^{15})$ | 11. | $-\text{CH}_2-\text{CCl}_3$ |
| 5 | 3. $-\text{CH}_2-\text{S}(\text{O})_2(\text{R}^{15})$ | 12. | $-\text{C}_6\text{H}_5$ |
| | 4. $-\text{CH}_2-\text{O}-\text{C}(\text{O})-\text{CH}_2-\text{C}_6\text{H}_5$ | 13. | $-\text{NH}-\text{CH}_2-\text{C}(\text{O})\text{O}-\text{CH}_2\text{CH}_3$ |
| | 5. 3-cholesteryl | 14. | $-\text{N}(\text{CH}_3)-\text{CH}_2-\text{C}(\text{O})\text{O}-\text{CH}_2\text{CH}_3$ |
| | 6. 3-pyridyl | 15. | $-\text{NHR}^3$ |
| | 7. N-ethylmorpholino | 16. | $-\text{CH}_2-\text{O}-\text{C}(\text{O})-\text{C}_{10}\text{H}_{15}$ |
| 10 | 8. $-\text{CH}_2-\text{O}-\text{C}(\text{O})-\text{C}_6\text{H}_5$ | 17. | $-\text{CH}_2-\text{O}-\text{C}(\text{O})-\text{CH}(\text{CH}_3)_2$ |
| | 9. $-\text{CH}_2-\text{O}-\text{C}(\text{O})-\text{CH}_2\text{CH}_3$ | 18. | $-\text{CH}_2-\text{C}\# \text{H}(\text{OC}(\text{O})\text{CH}_2\text{R}^{15})-\text{CH}_2-$
$(\text{OC}(\text{O})\text{CH}_2\text{R}^{15})^*$ |

15



* - Each R^{15} is the same or different $\text{C}_1\text{-C}_6$ alkyl (includes methyl, ethyl, propyl, isopropyl and t-butyl).

- chiral center is (R), (S) or racemate.

Other esters that are suitable for use herein are described in EP 632,048.

To the extent any compound of this invention cannot be produced by one of the foregoing methods other methods will be apparent to the artisan referring to conventional methods (see for instance Liotta et al. "Compendium of Organic Synthesis Methods" (John Wiley & Sons, New York), Vol. 1, Ian T. Harrison and Shuyen Harrison, 1971; Vol. 2, Ian T. Harrison and Shuyen Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G. Wade, Jr., 1980; Vol. 5, Leroy G. Wade, Jr., 1984; and Vol. 6, Michael B. Smith; March, J., "Advanced Organic Chemistry, Third Edition", (John Wiley & Sons,

New York, 1985); as well as "Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry. In 9 Volumes", Barry M. Trost, Editor-in-Chief (Pergamon Press, New York, 1993 printing).

5

Examples

Compounds were synthesized as described and assayed for activity against HSV-1, HSV-2, CMV, VZV, vaccinia virus, MSV, HIV-1 and HIV-2 using conventional methods in which inhibition of virus induced cytopathicity in either E₆SM or HEL cell cultures is assayed (see for example De Clercq et al. "J. Infect. Dis." 141:563 (1981) and "Nature" 323:464 (1986), Snoeck et al. "Antiviral Res." 21:197 (1993), Snoeck et al. "J. Med. Vir." 42:338 (1994) and Baba et al. "Eur. J. Clin. Microbiol." 6:158 (1987)). The following viruses were included in the study: herpes simplex virus type 1 (HSV-1), strain KOS and TK-deficient strains B 2006 and VMW 1837, HSV-2 (strain G), vaccinia virus (VV) and vesicular stomatitis virus (VSV) in E₆SM cells; cytomegalovirus strain AD-169 and strain Davis (HEL cells), varicella-zoster virus (VZV) strain OKA (TK⁺), YS (TK⁺), 07/1 (TK⁻) and YS/R (TK⁻) in HEL cells. The cell cultures were inoculated with 100 CCID₅₀, 1 h virus adsorption period.

The inhibition of HIV-induced cytopathicity in MT-4 or CEM/O cells was performed as described in Balzarini et al, "Proc. Natl. Acad. Sci. USA" 86:332 (1989). The cell cultures were inoculated with 100 CCID₅₀ of HIV-1 (HTLV-III) or HIV-2 (strain LAV-2).

The inhibition of MSV-transformation of murine C3H/3T3 fibroblasts was determined according to Balzarini et al., "Proc. Natl. Acad. Sci. USA" 86:332 (1989). The cell cultures were inoculated with 80 focus-forming units of MSV (prepared according to De Clercq and Merigan, "Proc. Soc. Exp. Biol. Med." 137:590 (1971)).

The results are set forth in Tables 1-7. In these Tables, 6-cyprNH-DAP, 6-cyhexNH-DAP, 6-phenetNH-DAP, pyrrolidino or pyrrol, pip or piperidino, morpholino, benzhydrylamino and furfurylamino shall be understood to mean, respectively, 2-amino-6-(N-cyclopropyl)purine, 2-amino-6-(N-cyclohexyl)purine, 2-amino-6-(N-[2-phenyl]ethyl)purine, 6-(N-pyrrolo)purine, 6-(N-piperidino)purine, 6-(N-morpholino)purine, diphenylmethylaminopurine and 6-((2-furyl)methylamino)purine. The antiviral activities are expressed as EC₅₀ in µg/ml; NA=not active; ND=not determined.

In addition, the ability of selected compounds to suppress or inhibit stimulation of the immune system was evaluated by determining the metabolic activity of treated lymphocytes. Single-cell suspension of splenocytes

was prepared by passing the fragmented pooled spleens of mice through a fine Nylon sieve. Erythrocytes were removed by means of Red Blood Cell Lysing Buffer, Sigma, containing 0.83% ammonium chloride in 0.01 M Tris-HCl pH 7.5. After repeated thorough washing (twice in phosphate-buffered saline, once in incomplete RPMI-1640 medium), the cells were seeded in triplicate wells of 96-well U-bottom cell culture plates (Costar). The number of cells was 5×10^5 /well in final 100 μ l. They were cultured for 72 h (37°C, 5% CO₂, 100% relative humidity; Heraeus incubator) either in the absence of any mitogen, or in the presence of PWM (1 μ g/ml), or ConA (4 μ g/ml), or LPS (5 μ g/ml). Test compounds were added 10 to 30 min following application of mitogens (as well as to mitogen-unstimulated cells). Their final concentration ranged from 0.0005 to 500 μ M. Six hours prior to the collection of cells, they were pulsed with 0.5 μ Ci of ³H-thymidine. Cells were harvested onto glass microfiber filters using Dynatech Multimash Harvester 2000. Thymidine incorporation (cpm) was determined via liquid scintillation counting.

Determination of 50% inhibitory concentration (IC₅₀). The relationship between drug concentration and % inhibition of thymidine incorporation was described by the Hill equation in the form: % inhibition = $[CN/(IC_{50} + CN)] \times I_{max}$ (Eq. 1), where I_{max} is maximal inhibition of thymidine incorporation, IC_{50} the concentration inducing 50% inhibition of the maximal, and N is the so called "shape" factor. The fitting of the inhibition values to Eq. 1 and estimation of its parameters from the data was executed on a Hewlett-Packard 86B computer using an iteration procedure based on the Levenberg-Marquardt modification of the Gauss-Newton minimization algorithm. This data, including variation seen in duplicate or multiple ("m") determinations, is reported in Tables 6-8.

Table 1a

Antiviral Activity of N6-Substituted 9-(R)-(2-Phosphonomethoxypropyl)adenines (PMP-Derivatives)

6-Substituent	HSV-1 (KOS)	HSV- 2 (G)	HSV-1 TK B2006	HSV-1 TK VMW1837	CMV AD169	CMV Davis	VZV TK OKA	VZV TK YS	VZV TK 07/1	VZV TK YS/R	Vaccini- a virus
	150	70	>200	300	>100	>100	35	57.6	8	28	>200
Amino											
Dimethylamino	2	2	2	2	0.9	0.9	0.006	0.013	0.02	0.016	20
Ethylmethylamino	0.7	2	2	0.7	0.13	0.28	0.007	0.011	0.005	0.005	20
Diethylamino	7	20	20	20	3.3	3.6	0.045	0.126	0.107	0.112	20
Isobutylamino	4	20	20	20	3.6	3.6	0.021	0.079	0.083	0.041	40
Allylamino	2	2	7	2	0.9	0.8	0.016	0.032	0.011	0.015	70
Cyclopropylamino	2	2	2	0.7	0.6	0.35	0.009	0.013	0.004	0.007	20
Pyrrolidino	7	20	20	10	7.2	9	0.151	0.082	0.106	0.095	70
2-Dimethylaminoethylamino	2	7	7	0.7	1.1	1	0.038	0.039	0.022	0.03	70

Table 1b

**Antiviral Activity of N6-Substituted 9-(2-Phosphonomethoxypropyl)-
2,6-Diaminopurines (PMP-Derivatives)**

6-Substituent	HSV-1 (KOS)	HSV-1 2 (G)	HSV-1 TK B2006	HSV-1 TK VMW1837	CMV AD169	CMV Davl's	VZV TK OKA	VZV TK YS	VZV TK 07/1	VZV TK YS/R	Vaccini- a virus
(R)-N6-Substituted 2,6-Diaminopurines											
Amino	300	70	-	150	NA	NA	NA	NA	NA	NA	150
Dimethylamino	20	>100	>100	20	>50	>50	30	30	20	20	>100
1-Butylamino	70	>100	>100	70	>50	>50	30	50	30	35	>100
2-Butylamino	40	>100	>100	20	>50	>50	50	40	30	30	70
2-Methylpropylamino	NA	NA	NA	NA	>20	>20	>20	>20	>20	>20	NA
1-Pentylamino	NA	NA	ND	NA	>50	ND	>50	ND	ND	ND	NA
Cyclopropylamino	150	>400	10	150	>50	>50	15	30	37	45	300
Cyclopentylamino	150	>200	>200	>200	>50	>50	>50	>50	>50	>50	70
Cyclohexylamino	70	>100	20	20	>50	>50	30	12	40	25	>100
Pyrrolidino	>200	>200	400	>200	>50	>50	5	40	>50	>50	150
Piperidino	70	>100	>100	70	>50	>50	33	40	50	50	70
Morpholino	70	>100	>100	70	>50	>50	>50	20	40	50	>100
Benzylamino	70	>100	70	40	>50	>50	35	25	20	20	70
Furfurylamino	NA	300	ND	70	>50	ND	ND	ND	ND	ND	NA
2-Dimethylaminoethylamino	7	2	20	7	0.37	0.8	0.026	0.006	0.003	0.009	20
(S)-N6-Substituted 2,6-Diaminopurines											
Amino	150	70	-	150	NA	NA	NA	20	10	>40	25
Dimethylamino	0.7	2	2	4	1.2	0.9	0.01	0.017	0.026	0.023	20
Allylamino	7	20	20	20	6	7	0.026	0.13	0.12	0.1	70
Cyclopropylamino	2	2	2	2	1.3	0.92	0.007	0.014	0.013	0.011	20
Pyrrolidino	20	20	20	70	5	5	0.05	0.18	0.24	0.11	150

Table 2

**Antiviral Activity of N6-Substituted 9-(2-Phosphonomethoxyethyl)-
2,6-Diaminopurines**

6-Substituent	HSV-1 (KOS)	HSV-2 (G)	HSV-1 TK B2006	HSV-1 TK VMW1837	CMV AD169	CMV Davis	VZV TK OKA	VZV TK YS	VZV TK 07/1	VZV TK YS/R	Vaccinia virus
Amino	2	0.2	-	2	10	10	0.02	0.01	0.02	0.03	70
Dimethylamino	0.07	0.7	2	0.07	0.2	0.1	0.04	0.02	0.01	0.01	2
Ethylmethylamino	0.7	0.4	2	2	0.3	0.5	0.14	0.06	0.025	0.03	7
Allylamino	0.7	0.7	4	0.7	0.2	0.3	0.17	0.11	0.1	0.06	7
1-Butylamino	2	40	2	2	6	1.5	1.1	1.3	2	1.3	7
2-Butylamino	7	70	7	7	9	3	1.2	3	2	4.3	10
2-Methylpropylamino	2	7	7	7	0.8	1.2	0.16	0.17	0.32	0.15	20
Cyclopropylamino	0.2	0.7	0.2	0.2	0.2	0.12	0.009	0.03	0.08	0.06	0.7
Cyclopentylamino	2	20	2	10	5	2	1	2.35	3	1.35	20
Cyclohexylamino	2	7	2	0.7	1	2.5	1	1.4	0.2	0.2	20
Pyrolidino	2	10	0.7	7	2	0.8	0.2	0.38	0.85	1	20
Piperidino	0.7	7	10	0.7	0.9	1	1.4	0.9	0.2	0.2	4
Morpholino	7	20	10	7	10	10	1.5	8	4	6	70
Benzylamino	2	40	70	2	5	10	4	2	3	>50	20
Phenethylamino	20	20	NA	20	10	15	7	10	7	3.3	70
Phenylamino	70	70	70	70	7	7	1.2	3	1	2	300
Benzhydrylamino	2	7	20	2	1.2	1	0.06	0.05	0.029	0.032	20
α -Naphthylamino	150	150	NA	NA	>50	>50	20	50	25	ND	300
2-Dimethylaminoethyl- amino	7	2	10	7	0.2	0.3	0.03	0.026	0.02	0.022	20
3-Dimethylaminopropyl- amino	7	7	20	20	1.3	1	0.1	0.068	0.028	0.03	70

Table 3

Antiviral Activity of N6-Substituted 9-(2-Phosphonomethoxyethyl)adenines

6-Substituent	HSV-1 (KOS)	HSV-2 (G)	HSV-1 TK ⁺ 82006	HSV-1 TK ⁺ VMW1837	CMV AD169	CMV Davis	VZV TK ⁺ OKA	VZV TK ⁺ YS	VZV TK ⁺ 07/1	VZV TK ⁺ YS/R	Vaccinia virus
Amino	20	2	-	7	70	-	6	10	6	10	100
Dimethylamino	7	20	70	7	9	9	1.6	3.2	0.9	4	300
Diethylamino	2	2	7	0.7	0.9	0.8	0.016	0.029	0.013	0.007	20
2-Methylpropylamino	20	70	20	20	25	13	0.65	0.9	0.27	0.2	NA
Allylamino	2	7	7	2	0.5	0.5	0.032	0.02	0.016	0.01	20
Cyclopropylamino	40	150	ND	70	25	23	3.5	5	1.6	4	NA
Cyclohexylamino	20	20	70	20	11	9	1.4	1.5	0.4	0.8	>400
Pyrrolidino	20	70	ND	20	12	12	0.29	0.25	0.2	0.24	NA
Piperidino	20	70	ND	20	15	11	0.3	0.5	0.2	0.2	NA
2-Dimethylaminoethyl- amino	20	70	70	20	13	13	1.5	5	2	0.2	>200

Table 4
Anti-retroviral activity of 9-(2-Phosphonomethoxyethyl)purines
(PME-derivatives)

6-Substituent	MSV	HIV-1		HIV-2	
		MT-4	CEM	MT-4	CEM
N6-Substituted Adenine Derivatives					
Amino	1.14±0.04	>4			
Dimethylamino			>100		85±21.2
Diethylamino			>4		>4
Allylamino			8±5.7		5±1.4
Cyclohexylamino			>100		>100
2-Dimethylaminoethylamino			>100		75±35.4
N6-Substituted 2,6-Diaminopurine Derivatives					
Amino	0.60±0.33	2.67±1.53	ND	ND	ND
Dimethylamino	0.24±0.07	0.4±0.01	0.7±0.1	0.4±0.05	0.8
Ethylmethylamino	0.26±0.17	0.19±0.16	0.55±0.35	0.11±0.04	0.2±0
Allylamino	0.14±0.11	>100	>0.032		>0.032
1-Butylamino	4.08±2.12	2.15±2.13	2	2.3±2.3	1.4±0.85
2-Butylamino	3.2	1.97±0.08	3	2.0±0.2	3
2-Methylpropylamino	NA	>0.16	0.5	>0.16	0.3
Cyclopropylamino	0.11	0.11±0.05	0.16	0.1±0.03	0.16
Cyclopentylamino	2.62±1.77	>0.8	2	>0.8	1.75±0.35
Cyclohexylamino	0.26±0.6	5.7±4	20	4.8±4	>20
Pyrrolidino	0.75	1.88±0.25	2.17	2±0.3	1.65±1.2
Piperidino	0.75±0.6	3.0±1.3	>4	3.0±1.3	>4
Morpholino	3.4±2.3	15±0.2	>20	16±0.3	>20
Benzylamino	1.5±0.94	50±12	>20	49±21	>20
Phenethylamino	21.8±7.5	9.9±0.9	18±5.7	11.9±2.8	12.5±3.5
Phenylamino	4.68±0.79	56.3±14.1	63.3±32.1	35.1±22.3	35±7
α-Naphthylamino	47.6±33.1	90.0±17.3	>100	68.5±2.5	80±28
2-Dimethylaminoethylamino	0.20±0.02	3.25±0.75	5.5±2.1	2.39±0.77	2±0.7
3-Dimethylaminopropylamino	0.40±0.07	6.12±3.73	13.0±6.6	7.03±4.9	4±0

Table 5
Antiretroviral Activity of N6-Substituted
9-(R)-(2-Phosphonomethoxypropyl) Purines (PMP-derivatives)

6-Substituent	MSV	HIV-1		HIV-2	
		MT-4	CEM	MT-4	CEM
N6-Substituted Adenine Derivatives					
Amino	0.95±0.23	1.91±0.41		1.69±0.35	
Ethylmethylamino			5.5±2.1		4
Allylamino			12±2.8		12
Cyclopropylamino			10±0		9.5±3.5
2-Dimethylaminoethylamino			>4		>4
N6-Substituted 2,6-Diaminopurine Derivatives					
Amino	0.073±0.02	0.293±0	-	0.236±0.03	-
Dimethylamino	3.25±1.44	2.3±0.2	10	4.2±2.8	9±1.4
1-Butylamino	3.27±1.3	13.1±4.3	10	9.8±4.9	10
2-Butylamino	3.5±0.3	30±19	>100	25±15	>100
2-Methylpropylamino	22.7±12.7	57.4±17.8	5.5±2.1	55.9±14	5.5±2.1
1-Pentylamino	5.14	37.4±13	20	37.7±5.8	15±7.1
Cyclopropylamino	1.09±0.24	4.15±3	2	3.2±1.6	2.5±0.7
Cyclopentylamino	3.78±0.08	3.4±0.4	4.5±3.5	5.8±2.3	8.5±2.1
Cyclohexylamino	1.4±1.2	8.0±2	20±17	7±2.6	13±6
Pyrrolidino	5.09±1.65	36.9±5.7	50±14	47.7±7	50
Piperidino	12.6±10	>100	>100	>100	>100
Morpholino	6.1±2.3	>100	>100	>100	>100
Benzylamino	0.3±0.11	10.3±1.4	11±6	8±2.9	12.5±3.5
Furfurylamino	2±1	10	7.0±4.2	7.74±1.33	6.0±5.7
2-Dimethylaminoethylamino	0.77±0.34	6.23±4.48	7	4.65±2.59	3.3±1.1

Table 6

Compound	Antiviral activity (µg/ml)						Inhibition of Immunostimulation	
	HSV-1	HSV-2	CMV AD169	CMV Davis	VZV+ OKA	VZV- 07/1	EC ₅₀ (nM)	EC ₅₀ (nM)
PMEDAP	2	0.2	10	10	1	3	0.23 ± 0.02	0.23
PME-6-BuNH-DAP	2	40	6	1.5	1.3	1.3		2.5
PME-6-(2-bu)NH-DAP	7	70	9	3	1.2	2	1.07 ± 0.20	1.07
PME-6-IsobuNH-DAP	2	7	0.8/1.1	1.2/2.4	0.16	0.32	0.24 ± 0.003	0.24
PME-6-allylNH-DAP	0.7	0.7	0.28/0.2	0.3/0.85	0.17	0.1	0.0098 ± 0.0011	0.01
PME-6-cyprNH-DAP	0.2	0.7	0.2	0.12	0.009	0.08	0.048 ± 0.001	0.048
PME-6-cyhexNH-DAP	2	7	1	2.5	1	0.2	2.65 ± 0.11	2.65
PME-6-PheneNH-DAP	20	20	10	15	7	7	7.52 ± 0.34	7.52
PME-6-Me2NEINH-DAP	7	2	0.2	0.3	0.03	0.02	0.35 ± 0.02	0.35
PME-6-Me2NPrNH-DAP	7	7	1.3	1	0.1	0.028	0.48 ± 0.14	0.48
PME-6-Me2N-DAP	0.07	0.7	0.2	0.1	0.04	0.01	0.43 ± 0.04	0.43
PME-6-Et,MeN-DAP	0.7	0.4	0.3	0.5	0.14	0.025	0.17 ± 0.02	0.17
PME-6-pyrrol-DAP	2	10	2	0.9	0.2	0.85	0.42 ± 0.06	0.42
PME-6-pipN-DAP	0.7	7	0.9	1	1.4	0.2	0.46 ± 0.03	0.46
PMEA								
PME-allylNH-Pu	2	7	0.5	0.5	0.032	0.016	0.72 ± 0.11	0.72
PME-6-cyprNH-Pu	40	150	25	23	3.5	1.6	1.56 ± 0.13	1.56
PME-Et2NPu	2	2	0.9	0.8	0.016	0.013	1.09 ± 0.07	1.09
PME-6-pyrrolNPu	20	70	12	12	0.25	0.24		25
PME-PipNH-Pu	20	70	15	11	0.3	0.2	23.60 ± 1.55	23.6
BisPOM-PMEA							0.0020 ± 0.0004	0.002


Table 7

Compound	Antiviral activity (μg/ml)						Inhibition of Immunostimulation	
	HSV-1	HSV-2	CMV AD169	CMV Davis	VZV+ OKA	VZV- 07/1	EC ₅₀ (nM)	EC ₅₀ (nM)
PMEMAP	70	>400	>100	>100	60	27	10.16 ± 0.24	10.16
(R)-PMPDAP	300	70	NA	NA	NA	NA	8.00 ± 0.24	8
(R)-PMP-6-cyprNH-DAP	150	>400	>50	>50	15	37	17.90 ± 1.12	17.9
(R)-PMP-6-Me2NEINH-DAP	7	2	0.37	0.8	0.026	0.004	0.38 ± 0.02	0.38
(R)-PMP-6-BuNH-DAP	70	>100	>50	>50	35	20	81.3 ± 3.89	81.3
(R)-PMP-CyprNHPu	2	2	0.6	0.35	0.009	0.004	0.74 ± 0.07	0.74
(R)-PMP-allylNHPu	2	2	0.9	0.8	0.016	0.011	1.26 ± 0.09	1.26
(R)-PMP-6-iBuNHPu	4	20	3.6	3.6	0.021	0.083		10
(R)-PMP-6-pyrrolNPU	7	400	7.2	9	0.151	0.106		8
(R)-PMP-6-EI2N-Pu	7	20	3.3	3.6	0.045	0.107		13
(R)-PMP-6-Me2N-Pu	2	20	0.9	0.9	0.006	0.02		2.2
(R)-PMP-EiMeNPu	0.7	2	0.13	0.28	0.007	0.005	0.51 ± 0.09	0.51
(R)-PMP-Me2EiNPu	2	7	1.1	1	0.038	0.022	1.31 ± 0.19	1.31
(S)-PMPA	NA	NA	>100	>100	>40	>40	496 ± 15.6	496
(S)-PMP-DAP	150	70	NA	NA	20	25		5
(S)-PMP-6-allylNH-DAP	7	20	6	7	0.026	0.12		7
(S)-PMP-6-cyprNH-DAP	2	2	1.3	0.92	0.007	0.014		1.7
(S)-PMP-6-Me2N-DAP	0.7	2	1.2	0.9	0.01	0.026		2
(S)-PMP-6-pyrrolN-DAP	20	20	5	5	0.05	0.24		15


Table 8

STATISTICAL MEAN VALUES OF SUPPRESSION OF
IMMUNOSTIMULATORY ACTIVITY IN DIVERSE STRUCTURAL
GROUPS OF ACYCLIC NUCLEOTIDE ANALOGS


STRUCTURAL GROUP	n	EC ₅₀ (nM)	Δ
A	6	15.34±10.1	0.72-40
B	13	0.70±0.56	0.008-2.6
C	8	4.63±3.08	0.5-13
D	4	26.9±21.3	0.38-81
F	5	6.14±3.23	1.75-15




(A)




(B)




(C)



(E)



(F)




(D)

All citations are hereby expressly incorporated by reference. The following examples are illustrative and do not limit the scope of this invention.

5 The claims shall be construed to exclude any subject matter that, at the date of the invention demonstrable under 35 USC §104, would not have been patentable under applicable statutory and judicial authority. In particular, the claims are to be construed as excluding any subject matter in any prior art citation herein that would have been obvious under 35 USC §103 or is
10 anticipated under 35 USC §102, especially compounds disclosed and enabled in the citations set forth in the background above.

Claims

1. A method comprising treating a subject infected or at risk of infection by a DNA virus with a therapeutically acceptable dose of a compound having structure (1)



wherein

- Y independently is, OH, -OR³, -OCH(R¹⁶)OC(O)R³, a monophosphate, a diphosphate, an amino acid amidate, a polypeptide amidate, -NHR³, or -N(R³);
- 10 R³ independently is unsubstituted alkyl, aryl, alkenyl, alkynyl, alkaryl, alkynylaryl or alkenylaryl; R³ substituted by C₁-C₆ alkoxy, C₁-C₆ carboxylalkylester, halo, carboxy, hydroxyl, cyano, nitro, N-morpholino, or amino; and/or R³ wherein -CH₂- has been substituted by NH, S, or O;
- R^{2'} and R² independently are halo, NH₂, X or H, but at least one R² is X;
- 15 R¹ is CH₃, C≡CH, CH=CH₂, CH₂F or azidomethyl;
- R¹⁶ is H or R³; and
- X is -(CH₂)_m(O)_n(CH₂)_mN(R¹⁰)₂ wherein m is 0-2, n is 0-1, and R¹⁰ independently is
- H,
- 20 C₁-C₁₅ alkyl, C₂-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₆-C₁₅ arylalkynyl, C₂-C₁₅ alkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroaralkyl, C₅-C₆ aryl, C₂-C₆ heterocycloalkyl,
- C₂-C₁₅ alkyl, C₃-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₃-C₁₅ alkynyl, C₇-C₁₅ arylalkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅
- 25 heteroalkyl or C₃-C₆ heterocycloalkyl wherein methylene in the alkyl moiety not adjacent to N⁶ has been replaced by -O-,
- optionally both R¹⁰ are joined together with N to form a saturated or unsaturated C₂-C₅ heterocycle containing one or two N heteroatoms and optionally an additional O or S heteroatom,
- 30 or one of the foregoing R¹⁰ groups which is substituted with 1 to 3 halo, CN or N₃; but one or two R¹⁰ groups are not H; and


Z is N or CH, provided that the heterocyclic nucleus varies from purine by no more than one Z;

and the therapeutically acceptable salts thereof.

- 5 2. The method of claim 1 wherein the virus is VZV, R¹ is CH₃, Y is OH or OR³, R² is H and X is -N(CH₃)₂, -N(CH₃)(CH₂CH₃), -N(CH₂CH₃)₂, -NHCH(CH₃)(CH₂CH₃), -NHCH₂CH=CH₂, -NH(CH₂)₂CH=CH₂, -NH(cyclopropyl), -N-pyrrolo, -NH(CH₂)₂NH(CH₃)₂, -NH(CH₂)₃NH(CH₃)₂, -NH(CH₂)₂NH(CH₃)(CH₂CH₃), -NH(CH₂)₃NH(CH₃)(CH₂CH₃),
 10 -NH(CH₂)₂NH(cyclopropyl), -NH(CH₂)₃NH(cyclopropyl), -NH(CH₂)₂NHCH₂(cyclopropyl), -NH(CH₂)₃NHCH₂(cyclopropyl), -NH(CH₂)₂NHCH₂CH=CH₂, -NH(CH₂)₃NHCH₂CH=CH₂, -NHCH₂C≡CH or -NHCH₂CH=CH(Phe).
- 15 3. The method of claim 1 wherein R¹ is in the (S) configuration.
4. The method of claim 1 wherein R² is H.
5. The method of claim 1 wherein E is -CH(CH₃)CH₂- and the methyl
 20 group of E is in the (S) configuration.
6. The method of claim 1 wherein one R¹⁰ group is not H.
7. The method of claim 1 wherein both R¹⁰ groups are not H.
 25
8. The method of claim 1 wherein one R¹⁰ is C₃-C₄ cycloalkyl.
9. The method of claim 1 wherein one R¹⁰ is C₁-C₆-alkylamino-C₁-C₆-alkyl.
 30
10. The method of claim 1 wherein one R¹⁰ is C₂-C₁₅ alkenyl or C₃-C₁₅ alkynyl.
11. The method of claim 1 wherein one R¹⁰ is
 35 -(CH₂)₂N(CH₃)(CH₂CH₃), (CH₂)₂N(CH₃)₂, (CH₂)₃N(CH₃)₂, -CH₂NHCH₂CH₂OCH₂NH(CH₃)₂, -CH₂NHCH₂OCH₂N(CH₃)₂,

$-\text{CH}_2\triangleleft$, $-\text{CH}(\text{CH}_3)\triangleleft$, $-(\text{CH}_2)_2\text{OCH}_2\triangleleft$, \triangleleft , \diamond , $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{CH}=\text{CH}_2$,
 $-\text{CH}=\text{CH}_2$, $-\text{CH}(\text{CH}_3)(\text{CH}=\text{CH}_2)$, $-(\text{CH}_2)_2\text{OCH}_3$, $-(\text{CH}_2)_2\text{OCH}(\text{CH}_3)_2$, $-(\text{CH}_2)_2\text{N}\triangleleft$,
 $-(\text{CH}_2)_2\text{N}\square$, $-(\text{CH}_2)_2\text{N}\square$, $-(\text{CH}_2)_2\text{N}\triangleleft$, $-\text{CH}_2\text{CH}=\text{CHPh}$, $-\text{CH}_2\text{CH}=\text{CHCH}_3$
 or $-\text{CH}_2\text{C}\equiv\text{CH}$.

12. The method of claim 1 wherein R^1 is CH_3 in the (R) configuration.
- 5 13. The method of claim 1 wherein R^2 is H.
14. The method of claim 1 wherein R^1 is CH_3 .
15. The method of claim 1 wherein the compound is 9-(R)-(2-phosphonomethoxypropyl)-6-ethylmethyaminoadenine, 9-(R)-(2-phosphonomethoxypropyl)-6-allylaminoadenine, 9-(R)-(2-phosphonomethoxypropyl)-6-cyclopropylaminoadenine, 9-(R)-(2-phosphonomethoxypropyl)-6-(2-dimethylaminoethyl)aminoadenine or 9-(R)-(2-phosphonomethoxypropyl)-2-amino-6-(2-dimethylaminoethyl)aminoadenine.
- 10 15 16. A compound having structure (1)



wherein

- 20 Y independently is, OH, $-\text{OR}^3$, $-\text{OCH}(\text{R}^{16})\text{OC}(\text{O})\text{R}^3$, a monophosphate, a diphosphate, an amino acid amidate, a polypeptide amidate, $-\text{NHR}^3$, or $-\text{N}(\text{R}^3)$;
- R^3 independently is unsubstituted alkyl, aryl, alkenyl, alkynyl, alkaryl, alkynylaryl or alkenylaryl; R^3 substituted by C_1 - C_6 alkoxy, C_1 - C_6 carboxylalkylester, halo, carboxy, hydroxyl, cyano, nitro, N-morpholino, or
- 25 amino; and/or R^3 wherein $-\text{CH}_2-$ has been substituted by NH, S, or O;

$R^{2'}$ and R^2 independently are halo, NH_2 , X or H, but at least one R^2 is X;
 R^1 is CH_3 , $C\equiv CH$, $CH=CH_2$, CH_2F or azidomethyl;

R^{16} is H or R^3 ; and

X is $-(CH_2)_m(O)_n(CH_2)_mN(R^{10})_2$ wherein m is 0-2, n is 0-1, and

5 R^{10} independently is

H,

C_1 - C_{15} alkyl, C_2 - C_{15} alkenyl, C_6 - C_{15} arylalkenyl, C_6 - C_{15} arylalkynyl,
 C_2 - C_{15} alkynyl, C_1 - C_6 -alkylamino- C_1 - C_6 alkyl, C_5 - C_{15} aralkyl, C_6 - C_{15}
heteroaralkyl, C_5 - C_6 aryl, C_2 - C_6 heterocycloalkyl,

10 C_2 - C_{15} alkyl, C_3 - C_{15} alkenyl, C_6 - C_{15} arylalkenyl, C_3 - C_{15} alkynyl, C_7 -
 C_{15} arylalkynyl, C_1 - C_6 -alkylamino- C_1 - C_6 alkyl, C_5 - C_{15} aralkyl, C_6 - C_{15}
heteroalkyl or C_3 - C_6 heterocycloalkyl wherein methylene in the alkyl moiety
not adjacent to N^6 has been replaced by $-O-$,

optionally both R^{10} are joined together with N to form a
15 saturated or unsaturated C_2 - C_5 heterocycle containing one or two N
heteroatoms and optionally an additional O or S heteroatom,

or one of the foregoing R^{10} groups which is substituted with 1 to
3 halo, CN or N_3 ; but one or two R^{10} groups are not H; and

Z is N or CH, provided that the heterocyclic nucleus varies from purine
20 by no more than one Z; provided that when R^1 is CH_3 and R^2 is NH_2 then
 $-N(R^{10})_2$ is not dimethylamino, cyclopropylamino, cyclopentylamino,
cyclohexylamino, pyrrolidinoamino, piperidinoamino, morpholinoamino, or
benzylamino;


and the therapeutically acceptable salts thereof.

25

17. The compound of claim 16 wherein R^1 is azidomethyl or vinyl.

18. The compound of claim 16 wherein R^1 is CH_3 in the (S) configuration.

30 19. A compound having structure (2)



wherein

Y independently is, OH, $-OR^3$, $-OCH(R^{16})OC(O)R^3$, a monophosphate, a diphosphate, an amino acid amidate, a polypeptide amidate, $-NHR^3$, or $-N(R^3)$;

X is $-(CH_2)_m(O)_n(CH_2)_mN(R^{10})_2$ wherein m is 0-2, n is 0-1, and;


Z is N or CH, provided that the heterocyclic nucleus varies from purine

5 by no more than one Z;


R^3 independently is unsubstituted alkyl, aryl, alkenyl, alkynyl, alkaryl, alkynylaryl or alkenylaryl; R^3 is substituted by C₁-C₆ alkoxy, C₁-C₆ carboxylalkylester, halo, carboxy, hydroxyl, cyano, nitro, N-morpholino, or amino; and/or R^3 wherein $-CH_2-$ has been substituted by NH, S, or O;

10 $R^{2'}$ and R^2 independently are halo, NH_2 , X or H, but at least one R^2 is X;


E is $-(CH_2)_2-$, $-CH(CH_3)CH_2-$, $-CH(CH_2F)CH_2-$, $-CH(CH_2OH)CH_2-$, $-CH(CH=CH_2)CH_2-$, $-CH(C\equiv CH)CH_2-$, $-CH(CH_2N_3)CH_2-$,



(3)



(4)



(5)

$-CH(R^6)OCH(R^{6'})-$, $-CH(R^9)CH_2O-$ or $-CH(R^8)O-$, wherein the right hand bond is linked to the 9 position of the purine, monoazapurine or monodeazapurine heterocycle and wherein Y and the hydroxyl group of $-CH(CH_2OH)CH_2-$, R^4 , R^6 , R^8 , or R^9 are joined to form a 6 membered ring;

the broken line represents an optional double bond;

15 R^4 and R^5 are independently hydrogen, hydroxy, halo, amino or a substituent having 1-5 carbon atoms selected from acyloxy, alkoxy, alkylthio, alkylamino and dialkylamino;

R^6 and $R^{6'}$ are independently H, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl, or C₂-C₇ alkanoyl;

20 R^7 are independently are H, C₁-C₆ alkyl, or are taken together to form $-O-$ or $-CH_2-$;

R^8 is H, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl or C₁-C₆ haloalkyl;

R^9 is H, hydroxymethyl or acyloxymethyl; and

R^{10} independently is

H,

30 C₁-C₁₅ alkyl, C₂-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₆-C₁₅ arylalkynyl, C₂-C₁₅ alkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroaralkyl, C₅-C₆ aryl, C₂-C₆ heterocycloalkyl,

C₂-C₁₅ alkyl, C₃-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₃-C₁₅ alkynyl, C₇-C₁₅ arylalkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroalkyl or C₃-C₆ heterocycloalkyl wherein methylene in the alkyl moiety not adjacent to N⁶ has been replaced by -O-,

- 5 optionally both R¹⁰ are joined together with N to form a saturated or unsaturated C₂-C₅ heterocycle containing one or two N heteroatoms and optionally an additional O or S heteroatom, or one of the foregoing R¹⁰ groups which is substituted with 1 to 3 halo, CN or N₃; and but one or two R¹⁰ groups are not H;

10 R¹⁶ is H or R³; and

the therapeutically acceptable salts thereof;
provided, however, that

- (a) when E is -CH(CH₃)CH₂- and R² is NH₂, then X is not dimethylamino, cyclopropylamino, cyclopentylamino, cyclohexylamino,
15 pyrrolidinoamino, piperidinoamino, morpholinoamino or benzylamino;
(b) when E is -CH(CH₂OH)CH₂- and R² is H, then X is not dimethylamino, N-methyl-N-ethylamino or diethylamino; and
(c) when E is -(CH₂)₂- and R² is NH₂, then X is not C₅-C₇ cycloalkylamino or dimethylamino.

20

20. The compound of claim 19 wherein at least one Y is OR³ and R³ is aryl, ortho-(C₁-C₆ alkoxyaryl), -C₆H₄C(O)O (C₁-C₆ alkyl), or -OCH₂OC(O) (C₁-C₆ alkyl or aryl).

25 21. The compound of claim 19 which has the (R) or (S) configuration at an E chiral carbon atom.

22. The compound of claim 19 which has the (R) configuration.

30 23. The compound of claim 19 which has the (S) configuration.


24. The compound of claim 19 further excluding compounds wherein if E is -CH(CH₃)CH₂- and R² is NH₂, then X is not alkylamino, dialkylamino, aralkylamino, heteroaralkylamino, alkoxyamino or heterocyclic amino.

35

25. The compound of claim 19 further excluding compounds wherein if E is -CH(CH₃)CH₂- and R² is H or NH₂, then X is not alkylamino, dialkylamino, aralkylamino, heteroaralkylamino, alkoxyamino or heterocyclic amino.

dialkylamino, aralkylamino, heteroaralkylamino, alkoxyamino or heterocyclic amino.

26. The compound of claim 19 wherein R^{10} is C_3 - C_8 alkynyl or alkenyl which is unsubstituted or is substituted with 1 to 3 halo, CN or N_3 .
27. The compound of claim 19 wherein R^{10} is $-CH_2CH=CH_2$, $-CH(CH_3)CH=CH_2$, $-CH_2C(CH_3)=CH_2$, or $-CH_2CH=CH(CH_3)$.
28. A method for treatment of viral infections comprising administering to a subject a therapeutically effective amount of a compound of claim 19.
29. The method of claim 28 wherein the viral infection is HSV-1, HSV-2, CMV, VZV, vaccinia virus, or HHV-6.
30. The compound of claim 19 wherein one R^{10} group is not H.
31. The compound of claim 19 wherein both R^{10} groups are not H.
32. A compound having structure (1)



wherein

- Y independently is OH, $-OR^3$, $-OCH(R^{16})OC(O)R^3$, a monophosphate, a diphosphate, an amino acid amidate, a polypeptide amidate, $-NHR^3$, or $-N(R^3)$;
- R^3 independently is unsubstituted alkyl, aryl, alkenyl, alkynyl, alkaryl, alkynylaryl or alkenylaryl; R^3 substituted by C_1 - C_6 alkoxy, C_1 - C_6 carboxylalkylester, halo, carboxy, hydroxyl, cyano, nitro, N-morpholino, or amino; and/or R^3 wherein $-CH_2-$ has been substituted by NH, S, or O;
- $R^{2'}$ and R^2 independently are halo, NH_2 , X or H, but at least one R^2 is X;
- R^1 is CH_3 , $C\equiv CH$, $CH=CH_2$, CH_2F or azidomethyl;
- R^{16} is H or R^3 ; and

X is $-(CH_2)_m(O)_n(CH_2)_mN(R^{10})_2$ wherein m is 0-2, n is 0-1 and R^{10} independently is

H,

5 C_4 cycloalkyl, C_3 - C_4 cycloalkyl-substituted C_1 - C_2 alkyl, C_2 - C_{15} alkenyl, C_6 - C_{15} arylalkenyl, C_6 - C_{15} arylalkynyl, C_2 - C_{15} alkynyl, C_1 - C_6 -alkylamino- C_1 - C_6 alkyl, C_6 - C_{15} heteroaralkyl, C_5 - C_6 aryl, C_2 - C_6 heterocycloalkyl, $-CH(Phe)_2$, or C_3 - C_4 cycloalkyl which C_3 - C_4 cycloalkyl is mono-, di- or tri-substituted with C_1 - C_3 alkyl,

10 C_2 - C_{15} alkyl, C_3 - C_{15} alkenyl, C_6 - C_{15} arylalkenyl, C_3 - C_{15} alkynyl, C_7 - C_{15} arylalkynyl, C_1 - C_6 -alkylamino- C_1 - C_6 alkyl, C_5 - C_{15} aralkyl, C_6 - C_{15} heteroalkyl or C_3 - C_6 heterocycloalkyl wherein methylene in the alkyl moiety not adjacent to N^6 has been replaced by $-O-$,


optionally both R^{10} are joined together with N to form a saturated or unsaturated C_2 - C_5 heterocycle containing one or two N
15 heteroatoms and optionally an additional O or S heteroatom,

or one of the foregoing R^{10} groups which is substituted with 1 to 3 halo, CN or N_3 ; but one or two R^{10} groups are not H; and

Z is N or CH, provided that the heterocyclic nucleus varies from purine by no more than one Z;

20 and the therapeutically acceptable salts thereof.

33. A method comprising treating a subject requiring immunosuppression with a therapeutically effective dose of a compound having structure (1)



25 wherein

Y independently is, OH, $-OR^3$, $-OCH(R^{16})OC(O)R^3$, a monophosphate, a diphosphate, an amino acid amidate, a polypeptide amidate, $-NHR^3$, or $-N(R^3)$;

R^3 independently is unsubstituted alkyl, aryl, alkenyl, alkynyl, alkaryl, alkynylaryl or alkenylaryl; R^3 substituted by C_1 - C_6 alkoxy, C_1 - C_6
30 carboxylalkylester, halo, carboxy, hydroxyl, cyano, nitro, N-morpholino, or amino; and/or R^3 wherein $-CH_2-$ has been substituted by NH, S, or O;

$R^{2'}$ and R^2 independently are halo, NH_2 , X or H, but at least one R^2 is X;

R^1 is H, CH_3 , $C\equiv CH$, $CH=CH_2$, CH_2F or azidomethyl;

R^{16} is H or R^3 ; and

X is $-(CH_2)_m(O)_n(CH_2)_mN(R^{10})_2$ wherein m is 0-2, n is 0-1, and

5 R^{10} independently is

H,

C₁-C₁₅ alkyl, C₂-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₆-C₁₅ arylalkynyl, C₂-C₁₅ alkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroaralkyl, C₅-C₆ aryl, C₂-C₆ heterocycloalkyl;

10 C₂-C₁₅ alkyl, C₃-C₁₅ alkenyl, C₆-C₁₅ arylalkenyl, C₃-C₁₅ alkynyl, C₇-C₁₅ arylalkynyl, C₁-C₆-alkylamino-C₁-C₆ alkyl, C₅-C₁₅ aralkyl, C₆-C₁₅ heteroalkyl or C₃-C₆ heterocycloalkyl wherein methylene in the alkyl moiety not adjacent to N⁶ has been replaced by -O-,

optionally both R^{10} are joined together with N to form a
15 saturated or unsaturated C₂-C₅ heterocycle containing one or two N heteroatoms and optionally an additional O or S heteroatom,

or one of the foregoing R^{10} groups which is substituted with 1 to 3 halo, CN or N₃; but one or two R^{10} groups are not H; and

Z is N or CH, provided that the heterocyclic nucleus varies from purine
20 by no more than one Z;

and the therapeutically acceptable salts thereof.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CZ 96/00011

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07F9/6561 A61K31/675 C07H19/16 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07F A61K C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 253 412 (CESKOSLOVENSKA AKADEMIE VED ; REGA FOUNDATION (BE)) 20 January 1988 cited in the application see the whole document ---	1-33
Y	EP,A,0 454 427 (CESKOSLOVENSKA AKADEMIE VED ; UNIV REGA KATHOLIEKE (BE)) 30 October 1991 cited in the application see the whole document ---	1-33
Y	EP,A,0 468 119 (MERRELL DOW PHARMA) 29 January 1992 cited in the application see the whole document ---	1-33

	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* "A" document member of the same patent family

Date of the actual completion of the international search

12 July 1996

Date of mailing of the international search report

20. 08. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CZ 96/00011

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 481 214 (SQUIBB BRISTOL MYERS CO) 22 April 1992 cited in the application see the whole document ---	1-33
Y	WO,A,94 03467 (INST OF ORGANIC CHEMISTRY AND ;REGA STICHTING V Z W (BE); GILEAD S) 17 February 1994 cited in the application see the whole document ---	1-33
Y	WO,A,95 07920 (GILEAD SCIENCES INC ;BISCHOFBERGER NORBERT W (US); JONES ROBERT J) 23 March 1995 cited in the application see the whole document ---	1-33
Y	EP,A,0 434 450 (WELLCOME FOUND) 26 June 1991 cited in the application see the whole document ---	1-33
Y	EP,A,0 421 819 (WELLCOME FOUND) 10 April 1991 cited in the application see the whole document -----	1-33

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CZ96/00011

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-15, 28, 29, 33
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-15, 28, 29 and 33 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CZ 96/00011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0253412	20-01-88	AU-B- 600002	02-08-90
		AU-B- 7575987	21-01-88
		DK-B- 170646	20-11-95
		IE-B- 60117	01-06-94
		JP-B- 8022866	06-03-96
		JP-A- 63045289	26-02-88
		KR-B- 9504179	27-04-95
		US-A- 5142051	25-08-92

EP-A-0454427	30-10-91	AT-T- 131171	15-12-95
		AU-B- 7533091	07-11-91
		CA-A- 2040982	25-10-91
		DE-D- 69115108	18-01-96
		DE-T- 69115108	04-07-96
		JP-A- 6206888	26-07-94

EP-A-0468119	29-01-92	AU-B- 8110991	30-01-92
		CA-A- 2047390	25-01-92
		CN-A- 1059528	18-03-92
		EP-A- 0468866	29-01-92
		JP-A- 4330086	18-11-92

EP-A-0481214	22-04-92	CA-A- 2051239	15-03-92
		JP-A- 4230694	19-08-92

WO-A-9403467	17-02-94	CA-A- 2141589	17-02-94
		CZ-A- 9500272	13-12-95
		EP-A- 0654037	24-05-95
		JP-T- 8503927	30-04-96

WO-A-9507920	23-03-95	AU-B- 7875294	03-04-95
		AU-B- 7956594	03-04-95
		EP-A- 0719273	03-07-96
		EP-A- 0719274	03-07-96
		WO-A- 9507919	23-03-95

EP-A-0434450	26-06-91	AP-A- 196	30-06-92
		AU-B- 633672	04-02-93
		AU-B- 6841990	27-06-91
		CA-A- 2033044	23-06-91

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PL/CZ 96/00011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0434450		CN-A, B 1054981	02-10-91
		IL-A- 96748	31-07-95
		NZ-A- 236593	26-01-94
		PL-B- 167097	31-07-95
		US-A- 5206435	27-04-93

EP-A-0421819	10-04-91	AU-B- 637831	10-06-93
		AU-B- 6386390	11-04-91
		CA-A- 2027052	07-04-91
		JP-A- 3188022	16-08-91
		US-A- 5185437	09-02-93
